<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="review-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Neurosci.</journal-id>
<journal-title>Frontiers in Neuroscience</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Neurosci.</abbrev-journal-title>
<issn pub-type="epub">1662-453X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fnins.2023.1216489</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neuroscience</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Purinergic signaling via P2X receptors and mechanisms of unregulated ATP release in the outer retina and age-related macular degeneration</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Molcak</surname>
<given-names>Haydn</given-names>
</name>
<xref rid="aff1" ref-type="aff"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2334824/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jiang</surname>
<given-names>Kailun</given-names>
</name>
<xref rid="aff1" ref-type="aff"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1003773/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Campbell</surname>
<given-names>Christopher J.</given-names>
</name>
<xref rid="aff2" ref-type="aff"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1308955/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Matsubara</surname>
<given-names>Joanne A.</given-names>
</name>
<xref rid="aff1" ref-type="aff"><sup>1</sup></xref>
<xref rid="c001" ref-type="corresp"><sup>&#x002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/522120/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Matsubara Lab, Faculty of Medicine, Department of Ophthalmology and Visual Sciences, Eye Care Centre</institution>, <addr-line>Vancouver, BC</addr-line>, <country>Canada</country></aff>
<aff id="aff2"><sup>2</sup><institution>Paragon Ventures Inc</institution>, <addr-line>Vancouver, BC</addr-line>, <country>Canada</country></aff>
<author-notes>
<fn fn-type="edited-by" id="fn0001"><p>Edited by: Dan Wen, Central South University, China</p></fn>
<fn fn-type="edited-by" id="fn0002"><p>Reviewed by: Michael Risner, Vanderbilt University, United States; Francesco Di Virgilio, University of Ferrara, Italy</p></fn>
<corresp id="c001">&#x002A;Correspondence: Joanne A. Matsubara, <email>jms@mail.ubc.ca</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>11</day>
<month>07</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>17</volume>
<elocation-id>1216489</elocation-id>
<history>
<date date-type="received">
<day>03</day>
<month>05</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>26</day>
<month>06</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2023 Molcak, Jiang, Campbell and Matsubara.</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Molcak, Jiang, Campbell and Matsubara</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Age-related macular degeneration (AMD) is a chronic and progressive inflammatory disease of the retina characterized by photoceptor loss and significant central visual impairment due to either choroidal neovascularization or geographic atrophy. The pathophysiology of AMD is complex and multifactorial, driven by a combination of modifiable and non-modifiable risk factors, molecular mechanisms, and cellular processes that contribute to overall disease onset, severity, and progression. Unfortunately, due to the structural, cellular, and pathophysiologic complexity, therapeutic discovery is challenging. While purinergic signaling has been investigated for its role in the development and treatment of ocular pathologies including AMD, the potential crosstalk between known contributors to AMD, such as the complement cascade and inflammasome activation, and other biological systems, such as purinergic signaling, have not been fully characterized. In this review, we explore the interactions between purinergic signaling, ATP release, and known contributors to AMD pathogenesis including complement dysregulation and inflammasome activation. We begin by identifying what is known about purinergic receptors in cell populations of the outer retina and potential sources of extracellular ATP required to trigger purinergic receptor activation. Next, we examine evidence in the literature that the purinergic system accelerates AMD pathogenesis leading to apoptotic and pyroptotic cell death in retinal cells. To fully understand the potential role that purinergic signaling plays in AMD, more research is needed surrounding the expression, distribution, functions, and interactions of purinergic receptors within cells of the outer retina as well as potential crosstalk with other systems. By determining how these processes are affected in the context of purinergic signaling, it will improve our understanding of the mechanisms that drive AMD pathogenesis which is critical in developing treatment strategies that prevent or slow progression of the disease.</p>
</abstract>
<kwd-group>
<kwd>purinergic signaling</kwd>
<kwd>age-related macular degeneration</kwd>
<kwd>ATP</kwd>
<kwd>complement</kwd>
<kwd>inflammasome</kwd>
<kwd>P2X</kwd>
</kwd-group>
<counts>
<fig-count count="3"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="133"/>
<page-count count="13"/>
<word-count count="10907"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Visual Neuroscience</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="sec1">
<title>Introduction</title>
<p>Purinergic signaling is a form of extracellular signaling involving purine and pyrimidine nucleotides and nucleosides that act on purinergic receptors to mediate numerous cellular functions (<xref ref-type="bibr" rid="ref18">Burnstock, 2008</xref>). In total, there are three distinct classes of purinergic receptors known as P1, P2Y, and P2X receptors. P1 receptors are G protein-coupled receptors (GPCRs) that respond to adenosine (<xref ref-type="bibr" rid="ref21">Burnstock, 2018</xref>). P2Y receptors are GPCRs that respond to nucleotides such as adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP), adenosine, uridine triphosphate (UTP), uridine diphosphate (UDP), and UDP-glucose (<xref ref-type="bibr" rid="ref21">Burnstock, 2018</xref>). P2X receptors are unique and function as ligand-gated ion channels that respond exclusively to extracellular ATP (eATP) (<xref ref-type="bibr" rid="ref21">Burnstock, 2018</xref>). Purinergic signaling represents a set of phylogenetically ancient pathways that play a critical role in numerous cellular processes, bodily systems, and developmental stages, including proliferation, differentiation, migration, apoptosis, embryogenesis, organogenesis, and aging (<xref ref-type="bibr" rid="ref22">Burnstock and Dale, 2015</xref>; <xref ref-type="bibr" rid="ref47">Huang et al., 2021</xref>). Within the eye, purinergic signaling has been investigated for its role in the development and treatment of ocular pathologies such as age-related macular degeneration (AMD), glaucoma, and diabetic retinopathy (<xref ref-type="bibr" rid="ref126">Ye et al., 2021</xref>).</p>
<p>AMD is a leading cause of visual impairment and accounts for approximately 9% of all cases of blindness worldwide (<xref ref-type="bibr" rid="ref121">Wong et al., 2014</xref>). The pathophysiology of AMD is complex and multifactorial, driven by a combination of non-modifiable risk factors (e.g., aging, genetic predisposition) and modifiable risk factors (e.g., smoking, hypertension, body mass index, hypercholesterolemia, nutritional intake, UV light) that contribute to overall disease onset, severity, and progression (<xref ref-type="bibr" rid="ref6">Ambati and Fowler, 2012</xref>; <xref ref-type="bibr" rid="ref121">Wong et al., 2014</xref>; <xref ref-type="bibr" rid="ref79">Mitchell et al., 2018</xref>; <xref ref-type="bibr" rid="ref29">de Jong et al., 2020</xref>; <xref ref-type="bibr" rid="ref108">Stahl, 2020</xref>). AMD can be subdivided into early, intermediate, and advanced stages, with the advanced forms characterized by photoreceptor loss in the macula, the region of the retina responsible for central vision. There are two forms of advanced AMD. Wet (or exudative) AMD (~10% of cases) develops due to choroidal neovascularization (CNV), a form of abnormal angiogenesis in the choriocapillaris layers of the choroid, which results in the growth of neo-vessels breaching Bruch&#x2019;s membrane, causing photoreceptor death (<xref ref-type="bibr" rid="ref79">Mitchell et al., 2018</xref>). Dry (or non-exudative) AMD (~90% of cases) is a slowly progressing degenerative process whereby regions of retinal pigment epithelium (RPE), a monolayer of cells that combine with Bruch&#x2019;s membrane and form the outer blood-eye barrier, undergo cell death leading to geographic atrophy (GA) (<xref ref-type="bibr" rid="ref79">Mitchell et al., 2018</xref>). The early stages of both forms are characterized by the buildup of drusen deposits, which are composed of glycoproteins, lipids, and immunogenic factors. The drusen accumulate in the extracellular space between the RPE and Bruch&#x2019;s membrane and provoke a chronic proinflammatory milieu that triggers the development of AMD (<xref ref-type="bibr" rid="ref79">Mitchell et al., 2018</xref>).</p>
<p>Despite the emergence of anti-vascular endothelial growth factor (VEGF) agents to treat wet AMD, there are currently no therapies available to prevent the development of dry AMD aside from nutritional supplementation (AREDS formulation) (<xref ref-type="bibr" rid="ref4">Age-Related Eye Disease Study Research Group, 2001</xref>). However, in 2023, the FDA approved pegcetacoplan, a complement C3 inhibitor, to slow the progression of GA, providing some promise for those with late-stage GA. It is also possible for a portion of patients with wet AMD to develop severe vision loss and blindness by developing GA over time, further emphasizing the complex nature of AMD pathogenesis (<xref ref-type="bibr" rid="ref46">Holz et al., 2014</xref>; <xref ref-type="bibr" rid="ref92">Rasmussen and Sander, 2014</xref>; <xref ref-type="bibr" rid="ref3">Agarwal et al., 2015</xref>; <xref ref-type="bibr" rid="ref24">Chen and Kaiser, 2020</xref>). Thus, understanding the multiple mechanisms that drive AMD and the interplay between wet and dry forms, is crucial in developing treatment strategies that not only slow the progression of the disease, but ultimately prevent its development.</p>
<p>In the present review, we explore purinergic signaling and mechanisms of unregulated ATP release in the outer retina, and its potential significance in AMD pathogenesis. While there is evidence for an interplay between purinergic signaling and the mechanisms associated with AMD pathogenesis such as complement dysregulation, inflammasome activation, and sublytic membrane attack complex (MAC) deposition, few studies have addressed their detailed interactions. We first begin by identifying what is known about purinergic receptors in cell populations of the outer retina along with potential sources of eATP required to trigger purinergic receptor activation. Next, we examine evidence in the literature that the purinergic system accelerates AMD pathogenesis leading to apoptotic and pyroptotic cell death in RPE, photoreceptors, and choroidal cells.</p>
</sec>
<sec id="sec2">
<title>Purinergic signaling</title>
<p>The purinergic system is a form of cell signaling in which both purine and pyrimidine nucleotides and nucleosides act on extracellular purinergic receptors (<xref ref-type="bibr" rid="ref18">Burnstock, 2008</xref>). As outlined above, purinergic receptors are divided into two classes known as P1 and P2 receptors. P1 receptors are GPCRs that respond to the nucleoside adenosine (<xref ref-type="bibr" rid="ref21">Burnstock, 2018</xref>). In contrast, P2 receptors are nucleotide receptors that are further subdivided into P2X and P2Y receptors. P2Y receptors are GPCRs that respond to several nucleotides such as ATP, ADP, AMP, UTP, UDP, and UDP-glucose (<xref ref-type="bibr" rid="ref21">Burnstock, 2018</xref>). P2X receptors are ligand-gated ion channels that respond exclusively to eATP (<xref ref-type="bibr" rid="ref21">Burnstock, 2018</xref>). This review will focus on P2X receptors which are composed of two transmembrane domains with cytoplasmic amino-and carboxyl-terminals that polymerize to form homotrimeric or heterotrimeric channels permeable to cations such as sodium, potassium, and calcium (<xref ref-type="bibr" rid="ref52">Jacobson et al., 2020</xref>). In total, seven homotrimeric P2X receptors (P2X1-7) and several heterotrimeric P2X channels with hybrid properties exist (<xref ref-type="bibr" rid="ref91">Ralevic and Burnstock, 1998</xref>; <xref ref-type="bibr" rid="ref52">Jacobson et al., 2020</xref>; <xref ref-type="bibr" rid="ref98">Santiago et al., 2020</xref>; <xref ref-type="bibr" rid="ref49">Illes et al., 2021</xref>). <xref rid="tab1" ref-type="table">Table 1</xref> outlines the unique features of P2X1-7 receptors based on their functional and pharmacological properties (<xref ref-type="bibr" rid="ref49">Illes et al., 2021</xref>). For a comprehensive review of purinergic signaling and current developments in this field, please see <xref ref-type="bibr" rid="ref17">Burnstock (2006</xref>, <xref ref-type="bibr" rid="ref20">2017)</xref>.</p>
<table-wrap position="float" id="tab1">
<label>Table 1</label>
<caption>
<p>P2X receptors showing their molecular, pharmacologic, and functional properties [Adapted from <xref ref-type="bibr" rid="ref49">Illes et al. (2021)</xref>].</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th/>
<th align="center" valign="top">P2X1</th>
<th align="center" valign="top">P2X2</th>
<th align="center" valign="top">P2X3</th>
<th align="center" valign="top">P2X4</th>
<th align="center" valign="top">P2X5</th>
<th align="center" valign="top">P2X6</th>
<th align="center" valign="top">P2X7</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">ATP EC50 (&#x03BC;M)</td>
<td align="center" valign="top">0.56&#x2013;0.7</td>
<td align="center" valign="top">2&#x2013;8</td>
<td align="center" valign="top">0.5&#x2013;1</td>
<td align="center" valign="top">1&#x2013;10</td>
<td align="center" valign="top">0.44&#x2013;10</td>
<td align="center" valign="top">12</td>
<td align="center" valign="top">100</td>
</tr>
<tr>
<td align="left" valign="top">Desensitization</td>
<td align="center" valign="top">Rapid (&#x003C;1&#x2009;s)</td>
<td align="center" valign="top">Slow (&#x003E;20s) or no desensitization</td>
<td align="center" valign="top">Rapid (&#x003C;1&#x2009;s)</td>
<td align="center" valign="top">Slow (&#x003E;20s)</td>
<td align="center" valign="top">Slow (&#x003E;20s)</td>
<td align="center" valign="top">Slow (&#x003E;20s)</td>
<td align="center" valign="top">Slow (&#x003E;20s)</td>
</tr>
<tr>
<td align="left" valign="top">Function</td>
<td align="center" valign="top">Non-selective cationic channel</td>
<td align="center" valign="top">Non-selective cationic channel</td>
<td align="center" valign="top">Non-selective cationic channel</td>
<td align="center" valign="top">Non-selective cationic channel<break/>Permeability for Ca2+ among highest in P2X family</td>
<td align="center" valign="top">Non-selective cationic channel<break/>Permeable to chloride ions</td>
<td align="center" valign="top">Non-selective cationic channel</td>
<td align="center" valign="top">Non-selective cationic channel</td>
</tr>
<tr>
<td align="left" valign="top">Large Pore</td>
<td align="center" valign="top">No</td>
<td align="center" valign="top">Yes</td>
<td align="center" valign="top">No</td>
<td align="center" valign="top">Yes</td>
<td align="center" valign="top">-</td>
<td align="center" valign="top">-</td>
<td align="center" valign="top">Yes</td>
</tr>
<tr>
<td align="left" valign="top">Functional Heterotrimers</td>
<td align="center" valign="top">P2X2, P2X4, P2X5</td>
<td align="center" valign="top">P2X1, P2X3, P2X5, P2X6</td>
<td align="center" valign="top">P2X2</td>
<td align="center" valign="top">P2X1, P2X6</td>
<td align="center" valign="top">P2X1, P2X2</td>
<td align="center" valign="top">P2X2, P2X4</td>
<td align="center" valign="top">P2X4</td>
</tr>
<tr>
<td align="left" valign="top">Location/ Cellular Expression Within the Retina</td>
<td align="center" valign="top">Inner plexiform layer, Muller cells, endothelial cells, glial cells</td>
<td align="center" valign="top">Amacrine cells, Muller cells, neurons</td>
<td align="center" valign="top">Amacrine cells, neurons</td>
<td align="center" valign="top">Glial cells, endothelial cells, neurons, horizontal cells of retina, amacrine and ganglion cells of the retina, Muller cells</td>
<td align="center" valign="top">Amacrine cells</td>
<td align="center" valign="top">Nerve fiber layer</td>
<td align="center" valign="top">Plexiform layers, horizontal cells, photoreceptors, amacrine cells, ganglion cells, glial cells, RPE, choroid, Muller cells</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Due to its well-established role in several inflammatory processes, a significant quantity of research has been performed surrounding P2X7. However, normal extracellular concentrations of ATP are approximately 10&#x2009;nM under steady-state conditions, and the half maximal effective concentration (EC50) for P2X7 receptor activation is approximately 100&#x2009;&#x03BC;M. Furthermore, once ATP is released, it can be rapidly degraded by ecto-enzymes yielding ADP, AMP, and adenosine, further decreasing the concentrations of ATP available for P2X activation. This means that the concentration of ATP required to activate P2X7 receptors is considerably higher than that found under physiological conditions leading to past debate surrounding its physiological relevance, especially in early stages of disease or inflammatory processes (<xref ref-type="bibr" rid="ref123">Yang et al., 2011</xref>). However, with the novel introduction of plasma membrane luciferase (pmeLUC) which has made direct measurements of eATP possible, the concentration of eATP has been shown to reach 100&#x2013;200&#x2009;&#x03BC;M (<xref ref-type="bibr" rid="ref89">Pellegatti et al., 2005</xref>, <xref ref-type="bibr" rid="ref300">2008</xref>; <xref ref-type="bibr" rid="ref81">Morciano et al., 2017</xref>; <xref ref-type="bibr" rid="ref94">Romagnani et al., 2020</xref>). Additionally, positive allosteric modulators acting at P2X7 are released into circulation during inflammation, thus further increasing the affinity of P2X7 for ATP (<xref ref-type="bibr" rid="ref113">Tomasinsig et al., 2008</xref>; <xref ref-type="bibr" rid="ref54">Kahlenberg and Kaplan, 2013</xref>; <xref ref-type="bibr" rid="ref31">Di Virgilio et al., 2018</xref>). Secreted or membrane-bound ecto-kinases such as adenylate kinase, nucleoside monophosphokinases, and nucleoside diphosphokinases can also phosphorylate nucleosides to produce AMP, ADP, and ATP (<xref ref-type="bibr" rid="ref102">Schwiebert and Zsembery, 2003</xref>). Taken together, there are several mechanisms whereby the concentration of eATP is capable of activating any and all of the P2X family of receptors. While questions remain surrounding the underlying pathways of P2X7 signaling in AMD, there is a significant gap in the literature surrounding other members of the P2X family of receptors, including novel and hybrid properties of heterotrimers, that may play an important role in various cellular and inflammatory processes.</p>
</sec>
<sec id="sec3">
<title>Purinergic signaling in the retina</title>
<p>The organization of the retina has been well studied for its complex synaptic circuitry of retinal neurons, supported by two vascular beds, an inner (retinal) and outer (choroidal) retinal supply. The outer vascular bed is comprised of the choroidal circulation that supports the outer retina and plays an important homeostatic role for the retinal pigment epithelium (RPE) and photoreceptors (<xref rid="fig1" ref-type="fig">Figure 1</xref>). For cells of the inner neuroretina, RPE, choroid, and retinal vasculature, purinergic receptors from each receptor class are present (<xref ref-type="bibr" rid="ref123">Yang et al., 2011</xref>; <xref ref-type="bibr" rid="ref117">Wagner et al., 2013</xref>; <xref ref-type="bibr" rid="ref51">Jacobson and Civan, 2016</xref>). This is important, as purinergic signaling has been implicated in the proliferation, survival, death, migration, and differentiation of retinal cells throughout development, aging, and in disease states. For a review on purinergic signaling in the inner retina, please see <xref ref-type="bibr" rid="ref115">Ventura et al. (2019)</xref> and <xref ref-type="bibr" rid="ref97">Sanderson et al. (2014)</xref>. Here, we discuss the distribution and functions of purinergic receptors on cells present within the outer retina, including the RPE and choroid, that may influence and contribute to AMD pathogenesis (<xref rid="fig2" ref-type="fig">Figure 2</xref>).</p>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption>
<p>Complex architecture of the human retina. A schematic diagram of a cross-section through the retina. The layers of the neuroretina from inner to outer include: the retinal nerve fiber layer (RNFL), ganglion cell layer (GCL), inner plexiform layer (IPL), inner neuronal layer (INL), outer plexiform layer (OPL), and outer neuronal layer (ONL). Below the neuroretina is the retinal pigment epithelial layer (RPE) which is a monolayer of cells that sit on the extracellular matrix basement membrane, Bruch&#x2019;s membrane (BM). The outer retinal is supplied by the choroidal blood circulatory system, comprised of the choriocapillaris (CC), the small vessel layer (SL) and the large vessel layer (not shown). Blood vessels (BV) are depicted within the figure. The retinal neurons in the inner retina include bipolar cells (BC, dark green), ganglion cells (GC, pink), amacrine cells (AC, light green), horizontal cells (HC, red), and rod and cone photoreceptors (orange). Microglia (blue), astrocytes (purple) and the Muller cells, a specialized astrocyte (MC, black) are supportive glial cell types that provide homeostasis and metabolic support for the retina.</p>
</caption>
<graphic xlink:href="fnins-17-1216489-g001.tif"/>
</fig>
<fig position="float" id="fig2">
<label>Figure 2</label>
<caption>
<p><bold>(A)</bold> Complement activation with the formation of the C5b-9(n) leading to the formation of a MAC/PFTs complex. The fully formed MAC creates large, 10&#x2009;nm-wide pores initiating an ion flux cumulating in a calcium dependent cell lysis. As a result of cell lysis, high concentrations of ATP may be released into the local environment which can simulate P2X and activate downstream purinergic modification. Extracellular ATP similarly can activate P2Y. Extracellular adenosine is re-cycled back into the cytoplasm via the nucleoside transporters (NT). <bold>(B)</bold> Pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) such as toxins, pathogens, metabolites, crystalline substances, nucleic acids, ion flux, reactive oxygen species, and ATP stimulate toll-like receptors (TLRs) and c type lectin receptors (CLRs) leading to activation of NF-&#x03BA;B followed by the subsequent transcriptional upregulation of NOD-like receptor family pyrin domain containing 3 (NLRP3) and pro-interleukin-1&#x03B2;. The cascade as depicted leads to the formation of gasdermin-D (GSDMD) and pyroptotic cell death through activation of caspase-4/5, capase-1, and GSDMD-NT along with release of ATP and other pro-inflammatory factors such as IL-1b, IL-18, and TFN-&#x03B1;.</p>
</caption>
<graphic xlink:href="fnins-17-1216489-g002.tif"/>
</fig>
<sec id="sec4">
<title>Retinal pigment epithelium</title>
<p>The RPE is considered a primary site of pathology in AMD (<xref ref-type="bibr" rid="ref109">Strauss, 2005</xref>; <xref ref-type="bibr" rid="ref10">Bhutto and Lutty, 2012</xref>). It is supported by Bruch&#x2019;s membrane, an important extracellular matrix that separates the RPE from the choroidal blood supply. The RPE is positioned between the overlying outer segments of photoreceptors and the choroidal blood supply and combines the functions of epithelial and glial cells to act as both a barrier and supporting tissue for overlying photoreceptors (<xref ref-type="bibr" rid="ref109">Strauss, 2005</xref>; <xref ref-type="bibr" rid="ref10">Bhutto and Lutty, 2012</xref>). Indeed, communication between photoreceptors and the RPE is critical to retinal function and occurs through a small extracellular space that exists between the apical membrane of RPE cells and photoreceptors (<xref ref-type="bibr" rid="ref80">Mitchell and Reigada, 2008</xref>). Located within this space is an abundance of enzymes and a highly structured extracellular matrix that allows for many functional interactions between the RPE and photoreceptors to take place (<xref ref-type="bibr" rid="ref80">Mitchell and Reigada, 2008</xref>). For example, the RPE delivers nutrients from the choroidal blood supply to the photoreceptors, removes metabolic end products from photoreceptors, produces melanin granules to absorb stray light, and recycles molecules important for maintenance of the visual cycle (<xref ref-type="bibr" rid="ref109">Strauss, 2005</xref>; <xref ref-type="bibr" rid="ref80">Mitchell and Reigada, 2008</xref>; <xref ref-type="bibr" rid="ref10">Bhutto and Lutty, 2012</xref>). The RPE also plays an integral role in the daily renewal of photoreceptors through the recycling and resynthesis of spent outer segments (<xref ref-type="bibr" rid="ref109">Strauss, 2005</xref>; <xref ref-type="bibr" rid="ref80">Mitchell and Reigada, 2008</xref>; <xref ref-type="bibr" rid="ref10">Bhutto and Lutty, 2012</xref>).</p>
<p>While RPE cells have been found on exon level profiling to express all subtypes of purinergic receptors (<xref ref-type="bibr" rid="ref117">Wagner et al., 2013</xref>), the distribution of P2X receptors in human RPE cells is not completely known and few studies have explored the role of P2X receptors within the outer retina. For example, <xref ref-type="bibr" rid="ref123">Yang et al. (2011)</xref> found P2X7 receptor mRNA in human RPE cells and functional data indicating that in addition to P2X7, other P2X receptors such as P2X1, P2X2, P2X3, P2X4, and P2X5 may also be present. However, further studies are needed to understand the expression, localization, and functions of these receptors within RPE cells.</p>
<p>Perhaps the most well-characterized of these receptors in the RPE to date is the P2X7 receptor, which induces calcium signaling and the activation of numerous cellular pathways that lead to subsequent apoptosis in both native and cultured human RPE cells (<xref ref-type="bibr" rid="ref123">Yang et al., 2011</xref>). RPE cell death also results in the release of proinflammatory cytokines and further unregulated release of ATP thereby increasing the vulnerability of other cells to ATP-induced apoptosis (<xref ref-type="bibr" rid="ref123">Yang et al., 2011</xref>). Increasing concentrations of eATP released from stressed, injured, or damaged outer retinal cells (in the case of AMD and other retinal diseases) also influence aspects of their overall function as support cells for the inner neuroretina through cytokine and growth factor release and as a stimulant for proliferation and differentiation (<xref ref-type="bibr" rid="ref85">Notomi et al., 2011</xref>; <xref ref-type="bibr" rid="ref84">Niyadurupola et al., 2013</xref>; <xref ref-type="bibr" rid="ref86">Notomi et al., 2013</xref>; <xref ref-type="bibr" rid="ref26">Clapp et al., 2019</xref>; <xref ref-type="bibr" rid="ref90">Platania et al., 2019</xref>).</p>
<p>An important aspect of P2X signaling in RPE cells is that under physiological circumstances, these cells can maintain homeostasis and prevent ATP-induced apoptosis by expressing high levels of the enzymes CD39 and CD73 within their membranes. CD39 is an ectonucleoside triphosphate diphosphohydrolase (NTPDase) that rapidly hydrolyzes ATP and ADP to AMP, while CD73 is an ectonucleotidase that degrades AMP to adenosine (<xref ref-type="bibr" rid="ref61">Kukulski et al., 2011</xref>; <xref ref-type="bibr" rid="ref35">Dwyer et al., 2020</xref>). Interestingly, after being exposed to inflammatory factors, <xref ref-type="bibr" rid="ref128">Zhang et al. (2018)</xref> demonstrated that RPE cells can rapidly become CD73-negative. This was found to be the result of matrix metalloproteinase-9 (MMP-9)-mediated shedding of CD73 from the cell membrane of RPE after exposure to inflammatory factors <italic>in vitro</italic>, leading to impaired immune suppression, increased concentrations of eATP, and accelerated local inflammation in the AMD environment (<xref ref-type="bibr" rid="ref128">Zhang et al., 2018</xref>).</p>
</sec>
<sec id="sec5">
<title>Immune cells</title>
<p>All immune cells, whether of the myeloid or lymphoid lineage, express at least one P2X receptor subtype, and many express all seven subtypes (<xref ref-type="bibr" rid="ref19">Burnstock, 2016</xref>). Within the outer retina and choroid, these immune cells include resident retinal microglia, mast cells, lymphocytes, monocytes, and dendritic cells (<xref ref-type="bibr" rid="ref100">Sarma and Ward, 2011</xref>; <xref ref-type="bibr" rid="ref77">Merle et al., 2015a</xref>,<xref ref-type="bibr" rid="ref78">b</xref>; <xref ref-type="bibr" rid="ref30">Di Virgilio et al., 2017</xref>; <xref ref-type="bibr" rid="ref8">Behnke et al., 2020</xref>; <xref ref-type="bibr" rid="ref32">Di Virgilio et al., 2020</xref>; <xref ref-type="bibr" rid="ref87">Ogura et al., 2020</xref>).</p>
</sec>
<sec id="sec6">
<title>Microglia</title>
<p>Microglia are resident professional phagocytes of the CNS, similar in function to blood-borne peripheral immune cells including monocytes, macrophages, and lymphocytes. They possess a high density of P2X7 receptors (<xref ref-type="bibr" rid="ref48">Illes et al., 2017</xref>, <xref ref-type="bibr" rid="ref50">2020</xref>) in addition to P2X1 and P2X4 (<xref ref-type="bibr" rid="ref32">Di Virgilio et al., 2020</xref>). Further, their ability to function as scavengers by migrating toward and clearing insoluble photo-oxidized material found in drusen has been shown to result from purinergic signaling interactions, such as in the case of ATP and P2X7 receptor activation (<xref ref-type="bibr" rid="ref42">Gu and Wiley, 2018</xref>). Indeed, the heterogeneous expression of P2X1, P2X4, and P2X7 receptors on the surface of macrophages with varying ATP affinities may enable fine-tuning of macrophage responses to ATP (<xref ref-type="bibr" rid="ref43">Guo et al., 2007</xref>; <xref ref-type="bibr" rid="ref1">Adinolfi et al., 2018</xref>). This can result in distinct desensitization kinetics and diverse intracellular transduction pathways that contribute to numerous pro-inflammatory pathways in a concentration-dependent manner (<xref ref-type="bibr" rid="ref1">Adinolfi et al., 2018</xref>).</p>
<p>Genetic association studies have also investigated this link by identifying a unique haplotype containing a heterotrimeric combination of P2X4 and P2X7 subunits that increases an individual&#x2019;s risk of developing AMD due to impaired P2X7 function. This results in reduced phagocytic capacity of macrophages, delayed clearance of apoptotic cells, and leakage of ATP from necrotic cells (<xref ref-type="bibr" rid="ref41">Gu et al., 2013</xref>). Furthermore, P2X7-null mice models demonstrated reduced blood-borne macrophage phagocytosis activity resulting in thickening of Bruch&#x2019;s membrane, RPE dysfunction, and retinal stress at 12&#x2009;months of age (<xref ref-type="bibr" rid="ref116">Vessey et al., 2017</xref>), followed by Bruch&#x2019;s membrane thickening, RPE cell loss, retinal functional deficits, and signs of inflammation between the RPE and photoreceptors at 18&#x2009;months of age &#x2013; phenotypic characteristics consistent with early AMD (<xref ref-type="bibr" rid="ref116">Vessey et al., 2017</xref>). Taken together, communication between macrophages occurs, in part, via purinergic signaling.</p>
<p>Other studies also support the role of ATP in regulating macrophage chemotaxis and macrophage activation (<xref ref-type="bibr" rid="ref60">Kronlage et al., 2010</xref>; <xref ref-type="bibr" rid="ref53">Junger, 2011</xref>; <xref ref-type="bibr" rid="ref95">Sakaki et al., 2013</xref>). This outlines a potential mechanism for the role of purinergic signaling in the pathogenesis of AMD, whereby immune cells present within the outer retina are no longer able to manage the task of removing the constant supply of photoreceptor debris, leading to the progressive and damaging accumulation of drusen within Bruch&#x2019;s membrane, activation of bystander cells, worsening nutrient and oxygen support for the RPE, and a vicious cycle of RPE failure, neuronal cell death, and central vision loss (<xref ref-type="bibr" rid="ref109">Strauss, 2005</xref>; <xref ref-type="bibr" rid="ref131">Zumerle et al., 2019</xref>).</p>
</sec>
<sec id="sec7">
<title>Mast cells</title>
<p>Mast cells (MCs) are recognized as key components of inflammatory reactions and are implicated in several inflammatory diseases. They are responsive to toxins and microbes, as well as substances such as advanced glycation end products, complement factors, C-reactive protein, and ATP, all of which are implicated in AMD (<xref ref-type="bibr" rid="ref87">Ogura et al., 2020</xref>). Of the seven P2X receptors, only five (P2X1, P2X3, P2X4, P2X6, and P2X7) are expressed by MCs (<xref ref-type="bibr" rid="ref120">Wareham et al., 2009</xref>; <xref ref-type="bibr" rid="ref119">Wareham and Seward, 2016</xref>). These receptors play an important role in regulating MC activities, such as calcium influx and degranulation that results in the release of many pre-stored inflammatory mediators (<xref ref-type="bibr" rid="ref16">Bulanova and Bulfone-Paus, 2010</xref>). Inflammatory mediators include IL-1&#x03B2;, Nuclear factor kappa B (NF-&#x03BA;B), tumor necrosis factor &#x03B1; (TNF-&#x03B1;), serotonin, and kinins, along with the synthesis and secretion of an array of cytokines, chemokines, prostaglandins, leukotrienes, and growth and angiogenesis factors (i.e., platelet-derived growth factor and VEGF) (<xref ref-type="bibr" rid="ref38">Galli and Tsai, 2008</xref>; <xref ref-type="bibr" rid="ref16">Bulanova and Bulfone-Paus, 2010</xref>; <xref ref-type="bibr" rid="ref66">Kurashima et al., 2012</xref>; <xref ref-type="bibr" rid="ref111">Theoharides et al., 2012</xref>; <xref ref-type="bibr" rid="ref105">Shieh et al., 2014</xref>; <xref ref-type="bibr" rid="ref96">Salcman et al., 2021</xref>). These MC components can modulate the activity of cells in their proximity and lead to the generation of reactive oxygen species (ROS), promotion of chemotaxis, altered phagocytosis, degradation of underlying extracellular matrix (ECM), and other events contributing to an overall increase in inflammation (<xref ref-type="bibr" rid="ref11">Bhutto et al., 2016</xref>; <xref ref-type="bibr" rid="ref57">Kempuraj et al., 2016</xref>; <xref ref-type="bibr" rid="ref23">Caraffa et al., 2018</xref>).</p>
<p>In the pathogenesis of AMD, MC-derived tryptase release also results in the breakdown of collagens and activation of MMPs that degrade choroidal stroma and Bruch&#x2019;s membrane. This leads to thinning of the choroid and degeneration of the RPE, both of which are hallmarks of GA (<xref ref-type="bibr" rid="ref87">Ogura et al., 2020</xref>). Additionally, MC activation has been implicated in choroidal neovascularization through granzyme B release through intracellular immune-mediated cell death and extracellular ECM degradation (<xref ref-type="bibr" rid="ref75">Matsubara et al., 2020</xref>). This results in remodeling of the ECM in Bruch&#x2019;s membrane, breakdown of the blood-retina barrier, and slowing of metabolite transport between the choroidal blood supply and retina, which can contribute to drusen deposition, vascular leakage, disruption of choroidal endothelial cell function, and the release of sequestered VEGF from Bruch&#x2019;s membrane (<xref ref-type="bibr" rid="ref75">Matsubara et al., 2020</xref>).</p>
</sec>
<sec id="sec8">
<title>Choroid and retinal vasculature</title>
<p>The retina is nourished by two independent vascular supplies (<xref rid="fig1" ref-type="fig">Figure 1</xref>). The outer retina and photoreceptors are fed by the choroidal vasculature that lies directly beneath the photoreceptors and the RPE, while the inner retina is served by intrinsic retinal vasculature, branches of the central retinal artery that enter at the optic disc (<xref ref-type="bibr" rid="ref83">Newman, 2015</xref>). As autonomic innervation is absent in the generation of retinal vascular tone, the tone of these vessels must be generated by intrinsic mechanisms such as the release of vasoactive agents from neurons, glial cells, and vascular endothelial cells (<xref ref-type="bibr" rid="ref65">Kur et al., 2012</xref>; <xref ref-type="bibr" rid="ref83">Newman, 2015</xref>). For this reason, purinergic signaling involving ATP has been explored as a mechanism to generate tone in retinal arterioles (<xref ref-type="bibr" rid="ref64">Kur and Newman, 2014</xref>). Indeed, experiments have demonstrated that a reduction of endogenous eATP levels leads to arteriole dilation, while an increase in eATP levels leads to vessel constriction through altered P2X1 receptor activity (<xref ref-type="bibr" rid="ref65">Kur et al., 2012</xref>; <xref ref-type="bibr" rid="ref83">Newman, 2015</xref>).</p>
<p>Purinergic signaling also results in choroidal and retinal neovascularization through remodeling of existing vasculature and proteolytic degradation of the endothelial basal membrane and surrounding extracellular matrix via MMP-2 and MMP-9 activation (<xref ref-type="bibr" rid="ref122">Yancopoulos et al., 2000</xref>; <xref ref-type="bibr" rid="ref9">Berglin et al., 2003</xref>). Additionally, stimulation of P2X receptors promotes VEGF release and alters endothelial barrier properties depending on the type of receptors present and the local concentration of the nucleotides within the vasculature (<xref ref-type="bibr" rid="ref1">Adinolfi et al., 2018</xref>). For instance, chronic P2X receptor activation with ATP acting as a danger-associated molecular pattern (DAMP) at high concentrations leads to endothelial barrier destabilization and edema formation through impaired M&#x00FC;ller cell function in the induction, maintenance, and proper functioning of the blood&#x2013;retinal barrier (<xref ref-type="bibr" rid="ref103">Shen et al., 2012</xref>; <xref ref-type="bibr" rid="ref118">Wakx et al., 2016</xref>). Together, these processes can contribute to retinal degeneration under pathologic conditions such as the proinflammatory environment seen in AMD.</p>
</sec>
</sec>
<sec id="sec9">
<title>Mechanisms of ATP release</title>
<p>Broadly, mechanisms of intermittent ATP release can be the result of (1) cell damage or cell death (e.g., complement activation and MAC deposition, osmotic swelling, ischemia, inflammation, or apoptosis leading to the passive leakage of ATP from cells), (2) vesicular release, or (3) channel-mediated release (<xref ref-type="bibr" rid="ref16">Bulanova and Bulfone-Paus, 2010</xref>). However, sustained ATP release which is likely the ATP release of pathophysiological significance can also result from a multiplicity of pathways (<xref ref-type="bibr" rid="ref69">Lazarowski et al., 2003</xref>; <xref ref-type="bibr" rid="ref28">Dale et al., 2023</xref>; <xref ref-type="bibr" rid="ref33">Di Virgilio et al., 2023</xref>; <xref ref-type="bibr" rid="ref106">Shinozaki et al., 2023</xref>). Within the outer retina, several processes that contribute to AMD pathogenesis lead to ATP release (<xref rid="fig2" ref-type="fig">Figure 2</xref>). For example, activation of the complement cascade results in ATP release from MAC deposition leading to inflammasome activation, the release of pore-forming gasdermins, and pyroptosis. ATP release can also act as a feedforward method to trigger P2X receptors and further promote cell degeneration in the AMD outer retina. Recently, apoptosis has also been shown to release ATP as a &#x201C;find me&#x201D; signal through Pannexin 1 channels (<xref ref-type="bibr" rid="ref76">Medina et al., 2020</xref>).</p>
<sec id="sec10">
<title>Complement system</title>
<p>The complement system plays a central role in AMD pathogenesis, along with aspects of cellular immunity and homeostasis. It consists of a network of proteins that can be sequentially cleaved and activated through any of three distinct pathways: the classical pathway, the lectin pathway, and/or the alternative pathway (<xref ref-type="bibr" rid="ref93">Ricklin et al., 2010</xref>; <xref ref-type="bibr" rid="ref100">Sarma and Ward, 2011</xref>; <xref ref-type="bibr" rid="ref77">Merle et al., 2015a</xref>,<xref ref-type="bibr" rid="ref78">b</xref>). Each of these pathways converge in the terminal pathway of the complement system, which results in the formation of the C5b-9(n) MAC complex. Fully formed MAC creates large, 10&#x2009;nm-wide, pores in the membranes of pathogens and vulnerable host cells and can result in calcium dependent cell lysis (<xref ref-type="bibr" rid="ref100">Sarma and Ward, 2011</xref>; <xref ref-type="bibr" rid="ref77">Merle et al., 2015a</xref>,<xref ref-type="bibr" rid="ref78">b</xref>). For a comprehensive review of complement and its role in AMD, please see <xref ref-type="bibr" rid="ref7">Armento et al. (2021)</xref>.</p>
<p>As a result of cell lysis, high concentrations of ATP may be released into the local environment. This can stimulate P2X receptors and influence the recruitment and activation of numerous inflammatory cells such as retinal microglia, mast cells, and circulating lymphocytes, monocytes, and macrophages, as described above (<xref ref-type="bibr" rid="ref93">Ricklin et al., 2010</xref>; <xref ref-type="bibr" rid="ref100">Sarma and Ward, 2011</xref>; <xref ref-type="bibr" rid="ref77">Merle et al., 2015a</xref>,<xref ref-type="bibr" rid="ref78">b</xref>; <xref ref-type="bibr" rid="ref8">Behnke et al., 2020</xref>; <xref ref-type="bibr" rid="ref87">Ogura et al., 2020</xref>). Ultimately, this amplification loop can: (1) induce changes in the composition of Bruch&#x2019;s membrane, the choriocapillaris, and ECM, (2) impair transport properties, alter lipid metabolism, and result in the accumulation of drusen, and (3) lead to chronic inflammation, oxidative stress, and altered energy metabolism as seen in the pathogenesis of AMD (<xref ref-type="bibr" rid="ref7">Armento et al., 2021</xref>).</p>
<p>These findings are echoed by genetic studies where over 33 different loci associated with aspects of the complement system, ECM remodeling, and other pathways such as cholesterol metabolism have demonstrated an increased risk for the development of AMD (<xref ref-type="bibr" rid="ref59">Klein et al., 2005</xref>; <xref ref-type="bibr" rid="ref101">Schramm et al., 2014</xref>; <xref ref-type="bibr" rid="ref13">Black and Clark, 2016</xref>). Complement activation can also alter the expression of MMP-2 and MMP-9 in various cell types, including RPE (<xref ref-type="bibr" rid="ref400">Bandyopadhyay and Rohrer, 2012</xref>). As discussed above, this can result in ECM turnover, neovascularization due to imbalances in VEGF secretion, altered ATP metabolism due to interactions with extracellular nucleosides, and increased purinergic signaling.</p>
</sec>
<sec id="sec11">
<title>Sublytic MAC formation and pore forming toxins</title>
<p>MAC deposition does not always result in lysis of host cells due to the presence of regulatory proteins and active repair processes. For example, active repair processes such as MAC plugging, exocytosis, and endocytosis repair cell membranes and remove MAC pores before lysis can take place to limit sustained elevations in intracellular calcium (<xref ref-type="bibr" rid="ref63">Kunchithapautham and Rohrer, 2011</xref>). Other regulatory processes include CD59, a membrane-bound GPI-anchored protein that inhibits the addition of C9 into the C5b-8/9 complex on host cells, which limits mean MAC lesion size (<xref ref-type="bibr" rid="ref63">Kunchithapautham and Rohrer, 2011</xref>). Soluble inhibitors such as vitronectin or clusterin that bind to the C5b-7 structure of the MAC can also prevent its attachment to cell membranes, rendering it water-soluble and inactive (<xref ref-type="bibr" rid="ref63">Kunchithapautham and Rohrer, 2011</xref>). Notably, these changes in MAC lesion size and binding affect the kinetics of ATP release and ion flux thereby influencing aspects of purinergic signaling.</p>
<p>Under sublytic conditions, several effects have been described that are hypothesized to contribute to the development and progression of both dry and wet forms of AMD. For instance, sublytic MAC formation can activate signaling pathways related to calcium, receptor tyrosine kinases, phospholipase C, protein kinase C, phospholipase 2&#x03B1;, and other extracellular signal-regulated kinases (<xref ref-type="bibr" rid="ref27">Cybulsky et al., 2005</xref>; <xref ref-type="bibr" rid="ref36">Fosbrink et al., 2005</xref>). This can lead to changes in cellular response including secretion, adherence, aggregation, chemotaxis, cell division, and impacts on membrane function (<xref ref-type="bibr" rid="ref14">Bohana-Kashtan et al., 2004</xref>). In RPE cells, sublytic MAC increases the production of cytokines IL-6, IL-8, and MCP-1, which may contribute to early AMD (<xref ref-type="bibr" rid="ref71">Lueck et al., 2011</xref>). Increased expression of MMP-2 and MMP-9 and VEGF are also associated with sublytic MAC formation on RPE and correlate with both remodeling of the choriocapillaris and neovascular processes seen in wet AMD (<xref ref-type="bibr" rid="ref112">Thurman et al., 2009</xref>; <xref ref-type="bibr" rid="ref71">Lueck et al., 2011</xref>). This is because VEGF, present in granular vesicles, is secreted via exocytosis following depolarization of cell membranes through activation of voltage-gated calcium channels. Calcium influx also activates the Ras/Erk pathway known to be involved in the regulated secretion of VEGF (<xref ref-type="bibr" rid="ref63">Kunchithapautham and Rohrer, 2011</xref>). Additionally, P2X7 receptor activation also triggers VEGF release (<xref ref-type="bibr" rid="ref45">Hill et al., 2010</xref>; <xref ref-type="bibr" rid="ref2">Adinolfi et al., 2012</xref>). Thus, sublytic MAC formation and purinergic signaling influences intracellular signaling pathways that result in growth factor secretion (<xref ref-type="bibr" rid="ref71">Lueck et al., 2011</xref>).</p>
<p>Various membrane pore-forming toxins, such as &#x03B1;-haemolysin, leukotoxin, and &#x03B1;-toxin, have also been shown to exert their toxic effects through autocrine and paracrine signaling in human erythrocytes (<xref ref-type="bibr" rid="ref12">Birke et al., 2013</xref>) leading to complement-mediated lysis amplified by ATP release and P2X receptor activation (<xref ref-type="bibr" rid="ref12">Birke et al., 2013</xref>). Additionally, amyloid-&#x03B2; protein aggregates and other pore forming toxins may lead to sublytic membrane damage and subsequent release of cellular components such as ATP, IL-1&#x03B2;, and IL-18 (<xref ref-type="bibr" rid="ref99">Sanz et al., 2009</xref>; <xref ref-type="bibr" rid="ref25">Ciudad et al., 2020</xref>). However, the underlying mechanisms and processes surrounding complement amplification, MAC deposition, and P2X receptor activation are not yet fully understood. We hypothesize that MAC deposition leads to an increase in eATP and subsequent P2X receptor activation. This results in an enhancement of ion flux, which has an impact on mitochondrial potential, the formation of ROS, inflammasome activation, and other intracellular changes leading to a feedback loop that allows for more MAC deposition. Further research is needed to establish these connections.</p>
<p>Overall, sublytic MAC and pore formation results in the remodeling of the choriocapillaris which contributes to the buildup of drusen, enhances complement activation and NLRP3 inflammasome activity, and leads to increased inflammation through cytokine release and recruitment of immune cells. Chronic inflammatory changes impact the overlying RPE, and the outer retina responds through additional signaling resulting in CNV, or regression of the choriocapillaris forming &#x201C;ghost&#x201D; vessels, subsequent RPE loss, and photoreceptor death in GA (<xref ref-type="bibr" rid="ref62">Kumar-Singh, 2019</xref>).</p>
</sec>
<sec id="sec12">
<title>NLRP3 inflammasome activation</title>
<p>Inflammasomes are multimolecular complexes comprised of three protein constituents: a NOD-like receptor, the adaptor protein apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), and pro-caspase 1 (<xref ref-type="bibr" rid="ref67">Latz et al., 2013</xref>). Their activation consists of a two-step process in which both an initial priming signal and an activating signal are required (<xref ref-type="bibr" rid="ref67">Latz et al., 2013</xref>). The initial priming signal is initiated by pathogen-associated molecular patterns (PAMPs) that stimulate toll-like receptors (TLRs) leading to the activation of NF-&#x03BA;B followed by the subsequent transcriptional upregulation of NOD-like receptor family pyrin domain containing 3 (NLRP3) and pro-interleukin-1&#x03B2; (<xref ref-type="bibr" rid="ref67">Latz et al., 2013</xref>; <xref ref-type="bibr" rid="ref56">Kelley et al., 2019</xref>). This is especially important in non-immune cells such as the RPE where basal expression levels are considered insufficient to initiate inflammasome assembly (<xref ref-type="bibr" rid="ref114">Tseng et al., 2013</xref>; <xref ref-type="bibr" rid="ref82">Narendran et al., 2021</xref>). Next, an activation signal is provided by a broad variety of molecules classified as either PAMPs or damage-associated molecular patterns (DAMPs) such as toxins, pathogens, metabolites, crystalline substances, nucleic acids, ion flux, reactive oxygen species, and ATP (<xref ref-type="bibr" rid="ref67">Latz et al., 2013</xref>; <xref ref-type="bibr" rid="ref73">Malik and Kanneganti, 2017</xref>; <xref ref-type="bibr" rid="ref129">Zheng et al., 2020</xref>). In the case of P2X7 activation, eATP acting as a DAMP is detected by P2X7. Following activation, inflammasomes lead to a unique inflammatory programmed cell death pathway known as pyroptosis (<xref ref-type="bibr" rid="ref56">Kelley et al., 2019</xref>).</p>
<p>Pyroptosis is executed by a family of pore-forming proteins known as gasdermins (GSDMs) (<xref ref-type="bibr" rid="ref104">Shi et al., 2015</xref>). In humans, the current members of the GSDM family include GSDMA, GSDMB, GSDMC, GSDMD, and GSDME, which contain an autoinhibitory carboxyterminal domain and a pore-forming amino-terminal domain responsible for perforating the plasma membrane of cells (<xref ref-type="bibr" rid="ref88">Orning et al., 2019</xref>; <xref ref-type="bibr" rid="ref15">Broz et al., 2020</xref>; <xref ref-type="bibr" rid="ref70">Liu et al., 2021</xref>). Typically, pyroptotic cell death initiates following the activation of the NLRP3 inflammasome and most often results in GSDMD pore formation and release of ATP (<xref ref-type="bibr" rid="ref44">He et al., 2015</xref>; <xref ref-type="bibr" rid="ref55">Kayagaki et al., 2015</xref>; <xref ref-type="bibr" rid="ref104">Shi et al., 2015</xref>). Proinflammatory cytokines such as IL-1&#x03B2; and IL-18 are also released through the nonselective 10&#x2013;14&#x2009;nM gasdermin pore (<xref ref-type="bibr" rid="ref67">Latz et al., 2013</xref>; <xref ref-type="bibr" rid="ref127">Yu et al., 2021</xref>) which induce both inflammatory an apoptotic effects (<xref ref-type="bibr" rid="ref74">Martinon et al., 2002</xref>; <xref ref-type="bibr" rid="ref5">Ambati et al., 2013</xref>). However, while there are cytotoxic effects of IL-18 and IL-1&#x03B2; on the RPE, studies have also shown beneficial effects of inflammasome-mediated IL-18 release through the inhibition of neovascularization in an acute laser-induced injury model of neovascular AMD (<xref ref-type="bibr" rid="ref34">Doyle et al., 2012</xref>). These contrasting findings imply that a single factor (IL-18) or pathway (NLRP3 inflammasome activation) can be simultaneously anti-angiogenic and destructive to the RPE and that Toll-like receptor 3 (TLR3) activation may be beneficial in terms of decreasing choroidal neovascularization while also promoting RPE degeneration (<xref ref-type="bibr" rid="ref5">Ambati et al., 2013</xref>). In contrast to the reported anti-angiogenic effects of IL-18, IL-1&#x03B2; promotes neovascularization (<xref ref-type="bibr" rid="ref68">Lavalette et al., 2011</xref>).</p>
<p>Based on the mechanisms described above, activation of the NLRP3 inflammasome and various gasdermin proteins have been implicated in the pathogenesis of AMD and several pathways have been suggested to trigger inflammasome activation in the outer retina including lipofuscin component A2E, accumulated Alu RNA, drusen components, amyloid-&#x03B2;, lipid peroxidation products, photooxidative damage, lysosomal destabilizations, particulate matter, overexpression of VEGF, and eATP (<xref ref-type="bibr" rid="ref5">Ambati et al., 2013</xref>; <xref ref-type="bibr" rid="ref58">Kerur et al., 2013</xref>). For example, the formation of amyloid-&#x03B2; oligomers (A&#x03B2;Os), which are aggregates of amyloid-&#x03B2; peptides and a major proinflammatory component of drusen (<xref ref-type="bibr" rid="ref72">Luibl et al., 2006</xref>), can lead to RPE degeneration and GA through A&#x03B2;O-induced priming, assembly, and activation of the NLRP3 inflammasome in RPE cells. This occurs through a P2X7-mediated pathway, in which amyloid-&#x03B2; protein aggregates form a conductivity pore resulting in membrane damage and subsequent release of cellular components such as ATP and inflammatory mediators (<xref ref-type="bibr" rid="ref99">Sanz et al., 2009</xref>; <xref ref-type="bibr" rid="ref25">Ciudad et al., 2020</xref>). Like other mechanisms of NLRP3 inflammasome activation, A&#x03B2;O-induced AMD models have been demonstrated to result in the expression of GSDMD (<xref ref-type="bibr" rid="ref110">Sun et al., 2018</xref>), along with RPE cytotoxicity driven by mitochondrial dysfunction and ROS formation (<xref ref-type="bibr" rid="ref107">Sorbara and Girardin, 2011</xref>; <xref ref-type="bibr" rid="ref130">Zhou et al., 2011</xref>).</p>
<p>Additionally, repetitive element-derived <italic>Alu</italic> RNA transcripts, non-canonical targets of DICER1-mediated enzymatic degradation, accumulate in human GA following the loss of DICER1 expression and are capable of activating P2X7 and the NLRP3 inflammasome to cause cell death of the retinal pigment epithelium in GA (<xref ref-type="bibr" rid="ref37">Fowler et al., 2014</xref>). This is because <italic>Alu</italic> RNA transcripts can function as both priming and activating signals for inflammasome signaling (<xref ref-type="bibr" rid="ref5">Ambati et al., 2013</xref>; <xref ref-type="bibr" rid="ref58">Kerur et al., 2013</xref>). As a result of this pathway and the fact that <italic>Alu</italic> RNA transcripts require reverse transcriptase, multiple nucleoside reverse transcriptase inhibitors (NRTIs) have been investigated and found to be efficacious in inhibiting P2X7-mediated NLRP3 inflammasome activation in mouse models of GA, CNV, and other P2X7 driven diseases (<xref ref-type="bibr" rid="ref37">Fowler et al., 2014</xref>).</p>
<p>Links between purinergic signaling and NLRP3 inflammasome activation are also well-defined as a result of ATP acting as a paracrine or autocrine signal in response to cell death or other stimuli (i.e., increased pressure, hypoxic injury, or complement-mediated damage). In these scenarios, the high amount of passive ATP release from cells activates the inflammasome through a P2X7R-dependent pyroptotic cell death pathway (<xref ref-type="bibr" rid="ref124">Yang et al., 2015</xref>). Activated caspase-11 may also cleave pannexin-1 channels, inducing ATP release and P2X7R-related pyroptosis (<xref ref-type="bibr" rid="ref124">Yang et al., 2015</xref>). Other nucleotide metabolites such as ADP, UTP, UDP, UDP glucose, and adenosine, along with other members of the purinergic receptor family (i.e., P2X, P2Y, and P1 receptors), may also contribute through complex purinergic signaling networks (<xref ref-type="bibr" rid="ref40">Gombault et al., 2013</xref>).</p>
<p>Taken together, an increasing body of evidence suggests that the retina can respond to diverse danger signals including unregulated ATP release via purinergic signaling leading to NLRP3 inflammasome activation (<xref ref-type="bibr" rid="ref40">Gombault et al., 2013</xref>; <xref ref-type="bibr" rid="ref39">Gao et al., 2015</xref>; <xref ref-type="bibr" rid="ref125">Yang et al., 2020</xref>), GSDM pore formation, and pyroptosis. Therefore, inhibition of P2X receptors and NLRP3 activation has been identified as putative drug targets in several models of AMD progression by delaying RPE degeneration in GA and/or slowing RPE barrier breakdown and neovascularization in CNV.</p>
</sec>
</sec>
<sec sec-type="conclusions" id="sec13">
<title>Conclusion</title>
<p>Purinergic signaling has been investigated for its role in the development of ocular pathologies such as AMD, glaucoma, and diabetic retinopathy. Despite the emergence of anti-VEGF agents to treat the wet form of late AMD, and the recently FDA-approved pegcetacoplan, a complement C3 inhibitor, to slow the progression of the dry form of late AMD, there are no approved drugs available to prevent the development of wet or dry AMD. For this reason, potential crosstalk between known contributors to AMD, such as complement dysregulation and inflammasome activation, and other cellular systems, such as purinergic signaling, must be considered (<xref rid="fig3" ref-type="fig">Figure 3</xref>).</p>
<fig position="float" id="fig3">
<label>Figure 3</label>
<caption>
<p>Overview of mechanisms of ATP release and purinergic signaling in the pathogenesis of AMD.</p>
</caption>
<graphic xlink:href="fnins-17-1216489-g003.tif"/>
</fig>
<p>As outlined in this review, the current literature surrounding purinergic signaling and AMD pathogenesis has focused primarily on the role of P2X7 receptor signaling. However, P2X7 has the highest EC50 for ATP in the P2X receptor family and may not be physiologically relevant throughout all stages of the development and progression of AMD, especially in the early stages of the disease. On the other hand, in advanced stages and under certain conditions, mechanisms may allow for P2X7 receptor activation through altered regulatory proteins, repair processes, and interactions between mediators such as MMPs and ectonucleosides leading to increased concentrations of ATP, increased purinergic signaling, and accelerated local inflammation contributing to the AMD pathogenesis.</p>
<p>To fully understand the potential roles that purinergic signaling plays in AMD, more research is needed surrounding the expression, distribution, functions, and interactions of P2X receptors with other systems, such as complement activation, within cells of the outer retina, RPE, choroid, retinal vasculature, and the immune system. This must include further characterization of both homotrimeric purinergic receptors, such as P2X1, P2X2, P2X3, P2X4, P2X5, and P2X6, along with heterotrimeric receptors that can exhibit novel properties and functions.</p>
<p>Finally, while there are numerous mechanisms for ATP release within the outer retina, the role of purinergic signaling in both lytic and sublytic processes should be explored in the context of how these processes may amplify complement-induced lysis, a mechanism that has not yet been fully elucidated. This may involve processes that make cells more vulnerable to MAC deposition following P2X activation, such as crosstalk between complement and P2X receptor signaling, MMP-9 activation, and other spatial and temporal aspects of ATP release. In determining how these processes can influence and be influenced by purinergic signaling, it will improve our understanding of the mechanisms that drive AMD pathogenesis, which is critical in developing treatment strategies that prevent or slow the progression of the disease.</p>
</sec>
<sec id="sec14">
<title>Author contributions</title>
<p>HM performed the data collection and analysis. HM, KJ, and JM wrote the manuscript. JM and CC conceived the review, obtained funding, and critically revised the manuscript. All authors have read and approved the final manuscript.</p>
</sec>
<sec sec-type="COI-statement" id="sec15">
<title>Conflict of interest</title>
<p>CC was employed by Paragon Ventures Inc.</p>
<p>The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="sec100" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</body>
<back>
<ack>
<p>The authors would like to thank Lucas Chang for help in data collection and analysis in early stages of the review process.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="ref1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adinolfi</surname> <given-names>E.</given-names></name> <name><surname>Giuliani</surname> <given-names>A. L.</given-names></name> <name><surname>De Marchi</surname> <given-names>E.</given-names></name> <name><surname>Pegoraro</surname> <given-names>A.</given-names></name> <name><surname>Orioli</surname> <given-names>E.</given-names></name> <name><surname>Di Virgilio</surname> <given-names>F.</given-names></name></person-group> (<year>2018</year>). <article-title>The P2X7 receptor: a main player in inflammation</article-title>. <source>Biochem. Pharmacol.</source> <volume>151</volume>, <fpage>234</fpage>&#x2013;<lpage>244</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bcp.2017.12.021</pub-id>, PMID: <pub-id pub-id-type="pmid">29288626</pub-id></citation></ref>
<ref id="ref2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adinolfi</surname> <given-names>E.</given-names></name> <name><surname>Raffaghello</surname> <given-names>L.</given-names></name> <name><surname>Giuliani</surname> <given-names>A. L.</given-names></name> <name><surname>Cavazzini</surname> <given-names>L.</given-names></name> <name><surname>Capece</surname> <given-names>M.</given-names></name> <name><surname>Chiozzi</surname> <given-names>P.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>Expression of P2X7 receptor increases in vivo tumor growth</article-title>. <source>Cancer Res.</source> <volume>72</volume>, <fpage>2957</fpage>&#x2013;<lpage>2969</lpage>. doi: <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-1947</pub-id>, PMID: <pub-id pub-id-type="pmid">22505653</pub-id></citation></ref>
<ref id="ref3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname> <given-names>A.</given-names></name> <name><surname>Rhoades</surname> <given-names>W. R.</given-names></name> <name><surname>Hanout</surname> <given-names>M.</given-names></name> <name><surname>Soliman</surname> <given-names>M. K.</given-names></name> <name><surname>Sarwar</surname> <given-names>S.</given-names></name> <name><surname>Sadiq</surname> <given-names>M. A.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development</article-title>. <source>Clin. Ophthalmol.</source> <volume>9</volume>, <fpage>1001</fpage>&#x2013;<lpage>1015</lpage>. doi: <pub-id pub-id-type="doi">10.2147/OPTH.S74959</pub-id>, PMID: <pub-id pub-id-type="pmid">26089632</pub-id></citation></ref>
<ref id="ref4"><citation citation-type="journal"><person-group person-group-type="author"><collab id="coll1">Age-Related Eye Disease Study Research Group</collab></person-group> (<year>2001</year>). <article-title>A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8</article-title>. <source>Arch. Ophthalmol.</source> <volume>119</volume>, <fpage>1417</fpage>&#x2013;<lpage>1436</lpage>. doi: <pub-id pub-id-type="doi">10.1001/archopht.119.10.1417</pub-id></citation></ref>
<ref id="ref5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ambati</surname> <given-names>J.</given-names></name> <name><surname>Atkinson</surname> <given-names>J. P.</given-names></name> <name><surname>Gelfand</surname> <given-names>B. D.</given-names></name></person-group> (<year>2013</year>). <article-title>Immunology of age-related macular degeneration</article-title>. <source>Nat. Rev. Immunol.</source> <volume>13</volume>, <fpage>438</fpage>&#x2013;<lpage>451</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nri3459</pub-id>, PMID: <pub-id pub-id-type="pmid">23702979</pub-id></citation></ref>
<ref id="ref6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ambati</surname> <given-names>J.</given-names></name> <name><surname>Fowler</surname> <given-names>B. J.</given-names></name></person-group> (<year>2012</year>). <article-title>Mechanisms of age-related macular degeneration</article-title>. <source>Neuron</source> <volume>75</volume>, <fpage>26</fpage>&#x2013;<lpage>39</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuron.2012.06.018</pub-id>, PMID: <pub-id pub-id-type="pmid">22794258</pub-id></citation></ref>
<ref id="ref7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Armento</surname> <given-names>A.</given-names></name> <name><surname>Ueffing</surname> <given-names>M.</given-names></name> <name><surname>Clark</surname> <given-names>S. J.</given-names></name></person-group> (<year>2021</year>). <article-title>The complement system in age-related macular degeneration</article-title>. <source>Cell. Mol. Life Sci.</source> <volume>78</volume>, <fpage>4487</fpage>&#x2013;<lpage>4505</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00018-021-03796-9</pub-id>, PMID: <pub-id pub-id-type="pmid">33751148</pub-id></citation></ref>
<ref id="ref400"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bandyopadhyay</surname> <given-names>M.</given-names></name> <name><surname>Rohrer</surname> <given-names>B.</given-names></name></person-group> (<year>2012</year>). <article-title>Matrix metalloproteinase activity creates pro-angiogenic environment in primary human retinal pigment epithelial cells exposed to complement</article-title>. <source>Investigative ophthalmology &#x0026; visual science</source> <volume>53</volume>, <fpage>1953</fpage>&#x2013;<lpage>1961</lpage>. doi: <pub-id pub-id-type="doi">10.1167/iovs.11-8638</pub-id>, PMID: <pub-id pub-id-type="pmid">31897541</pub-id></citation></ref>
<ref id="ref8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Behnke</surname> <given-names>V.</given-names></name> <name><surname>Wolf</surname> <given-names>A.</given-names></name> <name><surname>Langmann</surname> <given-names>T.</given-names></name></person-group> (<year>2020</year>). <article-title>The role of lymphocytes and phagocytes in age-related macular degeneration (AMD)</article-title>. <source>Cell. Mol. Life Sci.</source> <volume>77</volume>, <fpage>781</fpage>&#x2013;<lpage>788</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00018-019-03419-4</pub-id>, PMID: <pub-id pub-id-type="pmid">31897541</pub-id></citation></ref>
<ref id="ref9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berglin</surname> <given-names>L.</given-names></name> <name><surname>Sarman</surname> <given-names>S.</given-names></name> <name><surname>van der Ploeg</surname> <given-names>I.</given-names></name> <name><surname>Steen</surname> <given-names>B.</given-names></name> <name><surname>Ming</surname> <given-names>Y.</given-names></name> <name><surname>Itohara</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2003</year>). <article-title>Reduced choroidal neovascular membrane formation in matrix metalloproteinase-2-deficient mice</article-title>. <source>Invest. Ophthalmol. Vis. Sci.</source> <volume>44</volume>, <fpage>403</fpage>&#x2013;<lpage>408</lpage>. doi: <pub-id pub-id-type="doi">10.1167/iovs.02-0180</pub-id>, PMID: <pub-id pub-id-type="pmid">12506102</pub-id></citation></ref>
<ref id="ref10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bhutto</surname> <given-names>I.</given-names></name> <name><surname>Lutty</surname> <given-names>G.</given-names></name></person-group> (<year>2012</year>). <article-title>Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch's membrane/choriocapillaris complex</article-title>. <source>Mol. Asp. Med.</source> <volume>33</volume>, <fpage>295</fpage>&#x2013;<lpage>317</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.mam.2012.04.005</pub-id>, PMID: <pub-id pub-id-type="pmid">22542780</pub-id></citation></ref>
<ref id="ref11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bhutto</surname> <given-names>I. A.</given-names></name> <name><surname>McLeod</surname> <given-names>D. S.</given-names></name> <name><surname>Jing</surname> <given-names>T.</given-names></name> <name><surname>Sunness</surname> <given-names>J. S.</given-names></name> <name><surname>Seddon</surname> <given-names>J. M.</given-names></name> <name><surname>Lutty</surname> <given-names>G. A.</given-names></name></person-group> (<year>2016</year>). <article-title>Increased choroidal mast cells and their degranulation in age-related macular degeneration</article-title>. <source>Br. J. Ophthalmol.</source> <volume>100</volume>, <fpage>720</fpage>&#x2013;<lpage>726</lpage>. doi: <pub-id pub-id-type="doi">10.1136/bjophthalmol-2015-308290</pub-id>, PMID: <pub-id pub-id-type="pmid">26931413</pub-id></citation></ref>
<ref id="ref12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Birke</surname> <given-names>K.</given-names></name> <name><surname>Lipo</surname> <given-names>E.</given-names></name> <name><surname>Birke</surname> <given-names>M. T.</given-names></name> <name><surname>Kumar-Singh</surname> <given-names>R.</given-names></name></person-group> (<year>2013</year>). <article-title>Topical application of PPADS inhibits complement activation and choroidal neovascularization in a model of age-related macular degeneration</article-title>. <source>PLoS One</source> <volume>8</volume>:<fpage>e76766</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0076766</pub-id>, PMID: <pub-id pub-id-type="pmid">24130789</pub-id></citation></ref>
<ref id="ref13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Black</surname> <given-names>J. R.</given-names></name> <name><surname>Clark</surname> <given-names>S. J.</given-names></name></person-group> (<year>2016</year>). <article-title>Age-related macular degeneration: genome-wide association studies to translation</article-title>. <source>Genet. Med.</source> <volume>18</volume>, <fpage>283</fpage>&#x2013;<lpage>289</lpage>. doi: <pub-id pub-id-type="doi">10.1038/gim.2015.70</pub-id>, PMID: <pub-id pub-id-type="pmid">26020418</pub-id></citation></ref>
<ref id="ref14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bohana-Kashtan</surname> <given-names>O.</given-names></name> <name><surname>Ziporen</surname> <given-names>L.</given-names></name> <name><surname>Donin</surname> <given-names>N.</given-names></name> <name><surname>Kraus</surname> <given-names>S.</given-names></name> <name><surname>Fishelson</surname> <given-names>Z.</given-names></name></person-group> (<year>2004</year>). <article-title>Cell signals transduced by complement</article-title>. <source>Mol. Immunol.</source> <volume>41</volume>, <fpage>583</fpage>&#x2013;<lpage>597</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.molimm.2004.04.007</pub-id></citation></ref>
<ref id="ref15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Broz</surname> <given-names>P.</given-names></name> <name><surname>Pelegr&#x00ED;n</surname> <given-names>P.</given-names></name> <name><surname>Shao</surname> <given-names>F.</given-names></name></person-group> (<year>2020</year>). <article-title>The gasdermins, a protein family executing cell death and inflammation</article-title>. <source>Nat. Rev. Immunol.</source> <volume>20</volume>, <fpage>143</fpage>&#x2013;<lpage>157</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41577-019-0228-2</pub-id>, PMID: <pub-id pub-id-type="pmid">31690840</pub-id></citation></ref>
<ref id="ref16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bulanova</surname> <given-names>E.</given-names></name> <name><surname>Bulfone-Paus</surname> <given-names>S.</given-names></name></person-group> (<year>2010</year>). <article-title>P2 receptor-mediated signaling in mast cell biology</article-title>. <source>Puriner. Signal.</source> <volume>6</volume>, <fpage>3</fpage>&#x2013;<lpage>17</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11302-009-9173-z</pub-id>, PMID: <pub-id pub-id-type="pmid">19921464</pub-id></citation></ref>
<ref id="ref17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname> <given-names>G.</given-names></name></person-group> (<year>2006</year>). <article-title>Purinergic signalling-an overview</article-title>. <source>Novartis Found. Symp.</source> <volume>276</volume>, <fpage>26</fpage>&#x2013;<lpage>281</lpage>. PMID: <pub-id pub-id-type="pmid">16805422</pub-id></citation></ref>
<ref id="ref18"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Burnstock</surname> <given-names>G.</given-names></name></person-group> (<year>2008</year>). &#x201C;<article-title>Purinergic System</article-title>&#x201D; in <source>Encyclopedia of molecular pharmacology</source>. eds. <person-group person-group-type="editor"><name><surname>Offermanns</surname> <given-names>S.</given-names></name> <name><surname>Rosenthal</surname> <given-names>W.</given-names></name></person-group> (<publisher-loc>Berlin, Heidelberg</publisher-loc>: <publisher-name>Springer</publisher-name>)</citation></ref>
<ref id="ref19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname> <given-names>G.</given-names></name></person-group> (<year>2016</year>). <article-title>P2X ion channel receptors and inflammation</article-title>. <source>Purinergic Signal.</source> <volume>12</volume>, <fpage>59</fpage>&#x2013;<lpage>67</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11302-015-9493-0</pub-id>, PMID: <pub-id pub-id-type="pmid">26739702</pub-id></citation></ref>
<ref id="ref20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname> <given-names>G.</given-names></name></person-group> (<year>2017</year>). <article-title>Purinergic signalling: therapeutic developments</article-title>. <source>Front. Pharmacol.</source> <volume>8</volume>:<fpage>661</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fphar.2017.00661</pub-id>, PMID: <pub-id pub-id-type="pmid">28993732</pub-id></citation></ref>
<ref id="ref21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname> <given-names>G.</given-names></name></person-group> (<year>2018</year>). <article-title>Purine and purinergic receptors</article-title>. <source>Brain Neurosci. Adv.</source> <volume>2</volume>:<fpage>2398212818817494</fpage>. doi: <pub-id pub-id-type="doi">10.1177/2398212818817494</pub-id>, PMID: <pub-id pub-id-type="pmid">32166165</pub-id></citation></ref>
<ref id="ref22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname> <given-names>G.</given-names></name> <name><surname>Dale</surname> <given-names>N.</given-names></name></person-group> (<year>2015</year>). <article-title>Purinergic signalling during development and ageing</article-title>. <source>Purinergic Signal.</source> <volume>11</volume>, <fpage>277</fpage>&#x2013;<lpage>305</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11302-015-9452-9</pub-id>, PMID: <pub-id pub-id-type="pmid">25989750</pub-id></citation></ref>
<ref id="ref23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caraffa</surname> <given-names>A. L.</given-names></name> <name><surname>Conti</surname> <given-names>C.</given-names></name> <name><surname>D Ovidio</surname> <given-names>C.</given-names></name> <name><surname>Gallenga</surname> <given-names>C. E.</given-names></name> <name><surname>Tettamanti</surname> <given-names>L.</given-names></name> <name><surname>Mastrangelo</surname> <given-names>F.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>New concepts in neuroinflammation: mast cells pro-inflammatory and anti-inflammatory cytokine mediators</article-title>. <source>J. Biol. Regul. Homeost. Agents</source> <volume>32</volume>, <fpage>449</fpage>&#x2013;<lpage>454</lpage>.</citation></ref>
<ref id="ref24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>E. R.</given-names></name> <name><surname>Kaiser</surname> <given-names>P. K.</given-names></name></person-group> (<year>2020</year>). <article-title>Therapeutic potential of the Ranibizumab port delivery system in the treatment of AMD: evidence to date</article-title>. <source>Clin. Ophthalmol.</source> <volume>14</volume>, <fpage>1349</fpage>&#x2013;<lpage>1355</lpage>. doi: <pub-id pub-id-type="doi">10.2147/OPTH.S194234</pub-id>, PMID: <pub-id pub-id-type="pmid">32546942</pub-id></citation></ref>
<ref id="ref25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ciudad</surname> <given-names>S.</given-names></name> <name><surname>Puig</surname> <given-names>E.</given-names></name> <name><surname>Botzanowski</surname> <given-names>T.</given-names></name> <name><surname>Meigooni</surname> <given-names>M.</given-names></name> <name><surname>Arango</surname> <given-names>A. S.</given-names></name> <name><surname>Do</surname> <given-names>J.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>A&#x03B2;(1-42) tetramer and octamer structures reveal edge conductivity pores as a mechanism for membrane damage</article-title>. <source>Nat. Commun.</source> <volume>11</volume>:<fpage>3014</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41467-020-16566-1</pub-id>, PMID: <pub-id pub-id-type="pmid">32541820</pub-id></citation></ref>
<ref id="ref26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Clapp</surname> <given-names>C.</given-names></name> <name><surname>Diaz-Lezama</surname> <given-names>N.</given-names></name> <name><surname>Adan-Castro</surname> <given-names>E.</given-names></name> <name><surname>Ramirez-Hernandez</surname> <given-names>G.</given-names></name> <name><surname>Moreno-Carranza</surname> <given-names>B.</given-names></name> <name><surname>Sarti</surname> <given-names>A. C.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Pharmacological blockade of the P2X7 receptor reverses retinal damage in a rat model of type 1 diabetes</article-title>. <source>Acta Diabetol.</source> <volume>56</volume>, <fpage>1031</fpage>&#x2013;<lpage>1036</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00592-019-01343-4</pub-id>, PMID: <pub-id pub-id-type="pmid">30982154</pub-id></citation></ref>
<ref id="ref27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cybulsky</surname> <given-names>A. V.</given-names></name> <name><surname>Takano</surname> <given-names>T.</given-names></name> <name><surname>Papillon</surname> <given-names>J.</given-names></name> <name><surname>Bijian</surname> <given-names>K.</given-names></name> <name><surname>Guillemette</surname> <given-names>J.</given-names></name></person-group> (<year>2005</year>). <article-title>Activation of the extracellular signal-regulated kinase by complement C5b-9</article-title>. <source>Am. J. Physiol. Renal Physiol.</source> <volume>289</volume>, <fpage>F593</fpage>&#x2013;<lpage>F603</lpage>. doi: <pub-id pub-id-type="doi">10.1152/ajprenal.00066.2005</pub-id>, PMID: <pub-id pub-id-type="pmid">15855657</pub-id></citation></ref>
<ref id="ref28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dale</surname> <given-names>N.</given-names></name> <name><surname>Butler</surname> <given-names>J.</given-names></name> <name><surname>Dospinescu</surname> <given-names>V. M.</given-names></name> <name><surname>Nijjar</surname> <given-names>S.</given-names></name></person-group> (<year>2023</year>). <article-title>Channel-mediated ATP release in the nervous system</article-title>. <source>Neuropharmacology</source> <volume>227</volume>:<fpage>109435</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuropharm.2023.109435</pub-id>, PMID: <pub-id pub-id-type="pmid">36690324</pub-id></citation></ref>
<ref id="ref29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Jong</surname> <given-names>E. K.</given-names></name> <name><surname>Geerlings</surname> <given-names>M. J.</given-names></name> <name><surname>den Hollander</surname> <given-names>A. I.</given-names></name></person-group> (<year>2020</year>). <article-title>Age-related macular degeneration</article-title>. <source>Genet. Genom. Eye Disease</source>, <volume>1</volume>,  <fpage>155</fpage>&#x2013;<lpage>180</lpage>. doi: <pub-id pub-id-type="doi">10.1016/B978-0-12-816222-4.00010-1</pub-id></citation></ref>
<ref id="ref30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Di Virgilio</surname> <given-names>F.</given-names></name> <name><surname>Dal Ben</surname> <given-names>D.</given-names></name> <name><surname>Sarti</surname> <given-names>A. C.</given-names></name> <name><surname>Giuliani</surname> <given-names>A. L.</given-names></name> <name><surname>Falzoni</surname> <given-names>S.</given-names></name></person-group> (<year>2017</year>). <article-title>The P2X7 receptor in infection and inflammation</article-title>. <source>Immunity</source> <volume>47</volume>, <fpage>15</fpage>&#x2013;<lpage>31</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2017.06.020</pub-id></citation></ref>
<ref id="ref31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Di Virgilio</surname> <given-names>F.</given-names></name> <name><surname>Giuliani</surname> <given-names>A. L.</given-names></name> <name><surname>Vultaggio-Poma</surname> <given-names>V.</given-names></name> <name><surname>Falzoni</surname> <given-names>S.</given-names></name> <name><surname>Sarti</surname> <given-names>A. C.</given-names></name></person-group> (<year>2018</year>). <article-title>Non-nucleotide agonists triggering P2X7 receptor activation and pore formation</article-title>. <source>Front. Pharmacol.</source> <volume>9</volume>:<fpage>39</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fphar.2018.00039</pub-id>, PMID: <pub-id pub-id-type="pmid">29449813</pub-id></citation></ref>
<ref id="ref32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Di Virgilio</surname> <given-names>F.</given-names></name> <name><surname>Sarti</surname> <given-names>A. C.</given-names></name> <name><surname>Coutinho-Silva</surname> <given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>Purinergic signaling, DAMPs, and inflammation</article-title>. <source>Am. J. Physiol. Cell Physiol.</source> <volume>318</volume>, <fpage>C832</fpage>&#x2013;<lpage>C835</lpage>. doi: <pub-id pub-id-type="doi">10.1152/ajpcell.00053.2020</pub-id></citation></ref>
<ref id="ref33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Di Virgilio</surname> <given-names>F.</given-names></name> <name><surname>Vultaggio-Poma</surname> <given-names>V.</given-names></name> <name><surname>Falzoni</surname> <given-names>S.</given-names></name> <name><surname>Giuliani</surname> <given-names>A. L.</given-names></name></person-group> (<year>2023</year>). <article-title>Extracellular ATP: A powerful inflammatory mediator in the central nervous system</article-title>. <source>Neuropharmacology</source> <volume>224</volume>:<fpage>109333</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuropharm.2022.109333</pub-id>, PMID: <pub-id pub-id-type="pmid">36400278</pub-id></citation></ref>
<ref id="ref34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Doyle</surname> <given-names>S. L.</given-names></name> <name><surname>Campbell</surname> <given-names>M.</given-names></name> <name><surname>Ozaki</surname> <given-names>E.</given-names></name> <name><surname>Salomon</surname> <given-names>R. G.</given-names></name> <name><surname>Mori</surname> <given-names>A.</given-names></name> <name><surname>Kenna</surname> <given-names>P. F.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components</article-title>. <source>Nat. Med.</source> <volume>18</volume>, <fpage>791</fpage>&#x2013;<lpage>798</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nm.2717</pub-id>, PMID: <pub-id pub-id-type="pmid">22484808</pub-id></citation></ref>
<ref id="ref35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dwyer</surname> <given-names>K. M.</given-names></name> <name><surname>Kishore</surname> <given-names>B. K.</given-names></name> <name><surname>Robson</surname> <given-names>S. C.</given-names></name></person-group> (<year>2020</year>). <article-title>Conversion of extracellular ATP into adenosine: a master switch in renal health and disease</article-title>. <source>Nat. Rev. Nephrol.</source> <volume>16</volume>, <fpage>509</fpage>&#x2013;<lpage>524</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41581-020-0304-7</pub-id>, PMID: <pub-id pub-id-type="pmid">32641760</pub-id></citation></ref>
<ref id="ref36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fosbrink</surname> <given-names>M.</given-names></name> <name><surname>Niculescu</surname> <given-names>F.</given-names></name> <name><surname>Rus</surname> <given-names>H.</given-names></name></person-group> (<year>2005</year>). <article-title>The role of c5b-9 terminal complement complex in activation of the cell cycle and transcription</article-title>. <source>Immunol. Res.</source> <volume>31</volume>, <fpage>37</fpage>&#x2013;<lpage>46</lpage>. doi: <pub-id pub-id-type="doi">10.1385/IR:31:1:37</pub-id>, PMID: <pub-id pub-id-type="pmid">15591621</pub-id></citation></ref>
<ref id="ref37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fowler</surname> <given-names>B. J.</given-names></name> <name><surname>Gelfand</surname> <given-names>B. D.</given-names></name> <name><surname>Kim</surname> <given-names>Y.</given-names></name> <name><surname>Kerur</surname> <given-names>N.</given-names></name> <name><surname>Tarallo</surname> <given-names>V.</given-names></name> <name><surname>Hirano</surname> <given-names>Y.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity</article-title>. <source>Science</source> <volume>346</volume>, <fpage>1000</fpage>&#x2013;<lpage>1003</lpage>. doi: <pub-id pub-id-type="doi">10.1126/science.1261754</pub-id>, PMID: <pub-id pub-id-type="pmid">25414314</pub-id></citation></ref>
<ref id="ref38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Galli</surname> <given-names>S. J.</given-names></name> <name><surname>Tsai</surname> <given-names>M.</given-names></name></person-group> (<year>2008</year>). <article-title>Mast cells: versatile regulators of inflammation, tissue remodeling, host defense and homeostasis</article-title>. <source>J. Dermatol. Sci.</source> <volume>49</volume>, <fpage>7</fpage>&#x2013;<lpage>19</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jdermsci.2007.09.009</pub-id>, PMID: <pub-id pub-id-type="pmid">18024086</pub-id></citation></ref>
<ref id="ref39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname> <given-names>J.</given-names></name> <name><surname>Liu</surname> <given-names>R. T.</given-names></name> <name><surname>Cao</surname> <given-names>S.</given-names></name> <name><surname>Cui</surname> <given-names>J. Z.</given-names></name> <name><surname>Wang</surname> <given-names>A.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>NLRP3 inflammasome: activation and regulation in age-related macular degeneration</article-title>. <source>Mediat. Inflamm.</source> <volume>2015</volume>, <fpage>1</fpage>&#x2013;<lpage>11</lpage>. doi: <pub-id pub-id-type="doi">10.1155/2015/690243</pub-id>, PMID: <pub-id pub-id-type="pmid">25698849</pub-id></citation></ref>
<ref id="ref40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gombault</surname> <given-names>A.</given-names></name> <name><surname>Baron</surname> <given-names>L.</given-names></name> <name><surname>Couillin</surname> <given-names>I.</given-names></name></person-group> (<year>2013</year>). <article-title>ATP release and purinergic signaling in NLRP3 inflammasome activation</article-title>. <source>Front. Immunol.</source> <volume>3</volume>:<fpage>414</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2012.00414</pub-id>, PMID: <pub-id pub-id-type="pmid">23316199</pub-id></citation></ref>
<ref id="ref41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname> <given-names>B. J.</given-names></name> <name><surname>Baird</surname> <given-names>P. N.</given-names></name> <name><surname>Vessey</surname> <given-names>K. A.</given-names></name> <name><surname>Skarratt</surname> <given-names>K. K.</given-names></name> <name><surname>Fletcher</surname> <given-names>E. L.</given-names></name> <name><surname>Fuller</surname> <given-names>S. J.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>A rare functional haplotype of the P2RX4 and P2RX7 genes leads to loss of innate phagocytosis and confers increased risk of age-related macular degeneration</article-title>. <source>FASEB J.</source> <volume>27</volume>, <fpage>1479</fpage>&#x2013;<lpage>1487</lpage>. doi: <pub-id pub-id-type="doi">10.1096/fj.12-215368</pub-id>, PMID: <pub-id pub-id-type="pmid">23303206</pub-id></citation></ref>
<ref id="ref42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname> <given-names>B. J.</given-names></name> <name><surname>Wiley</surname> <given-names>J. S.</given-names></name></person-group> (<year>2018</year>). <article-title>P2X7 as a scavenger receptor for innate phagocytosis in the brain</article-title>. <source>Br. J. Pharmacol.</source> <volume>175</volume>, <fpage>4195</fpage>&#x2013;<lpage>4208</lpage>. doi: <pub-id pub-id-type="doi">10.1111/bph.14470</pub-id>, PMID: <pub-id pub-id-type="pmid">30098011</pub-id></citation></ref>
<ref id="ref43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname> <given-names>C.</given-names></name> <name><surname>Masin</surname> <given-names>M.</given-names></name> <name><surname>Qureshi</surname> <given-names>O. S.</given-names></name> <name><surname>Murrell-Lagnado</surname> <given-names>R. D.</given-names></name></person-group> (<year>2007</year>). <article-title>Evidence for functional P2X4/P2X7 heteromeric receptors</article-title>. <source>Mol. Pharmacol.</source> <volume>72</volume>, <fpage>1447</fpage>&#x2013;<lpage>1456</lpage>. doi: <pub-id pub-id-type="doi">10.1124/mol.107.035980</pub-id></citation></ref>
<ref id="ref44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>He</surname> <given-names>W. T.</given-names></name> <name><surname>Wan</surname> <given-names>H.</given-names></name> <name><surname>Hu</surname> <given-names>L.</given-names></name> <name><surname>Chen</surname> <given-names>P.</given-names></name> <name><surname>Wang</surname> <given-names>X.</given-names></name> <name><surname>Huang</surname> <given-names>Z.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Gasdermin D is an executor of pyroptosis and required for interleukin-1&#x03B2; secretion</article-title>. <source>Cell Res.</source> <volume>25</volume>, <fpage>1285</fpage>&#x2013;<lpage>1298</lpage>. doi: <pub-id pub-id-type="doi">10.1038/cr.2015.139</pub-id>, PMID: <pub-id pub-id-type="pmid">26611636</pub-id></citation></ref>
<ref id="ref45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname> <given-names>L. M.</given-names></name> <name><surname>Gavala</surname> <given-names>M. L.</given-names></name> <name><surname>Lenertz</surname> <given-names>L. Y.</given-names></name> <name><surname>Bertics</surname> <given-names>P. J.</given-names></name></person-group> (<year>2010</year>). <article-title>Extracellular ATP may contribute to tissue repair by rapidly stimulating purinergic receptor X7-dependent vascular endothelial growth factor release from primary human monocytes</article-title>. <source>J. Immunol.</source> <volume>185</volume>, <fpage>3028</fpage>&#x2013;<lpage>3034</lpage>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1001298</pub-id>, PMID: <pub-id pub-id-type="pmid">20668222</pub-id></citation></ref>
<ref id="ref46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holz</surname> <given-names>F. G.</given-names></name> <name><surname>Schmitz-Valckenberg</surname> <given-names>S.</given-names></name> <name><surname>Fleckenstein</surname> <given-names>M.</given-names></name></person-group> (<year>2014</year>). <article-title>Recent developments in the treatment of age-related macular degeneration</article-title>. <source>J. Clin. Invest.</source> <volume>124</volume>, <fpage>1430</fpage>&#x2013;<lpage>1438</lpage>. doi: <pub-id pub-id-type="doi">10.1172/JCI71029</pub-id>, PMID: <pub-id pub-id-type="pmid">24691477</pub-id></citation></ref>
<ref id="ref47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>Z.</given-names></name> <name><surname>Xie</surname> <given-names>N.</given-names></name> <name><surname>Illes</surname> <given-names>P.</given-names></name> <name><surname>Di Virgilio</surname> <given-names>F.</given-names></name> <name><surname>Ulrich</surname> <given-names>H.</given-names></name> <name><surname>Semyanov</surname> <given-names>A.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>From purines to purinergic signalling: molecular functions and human diseases</article-title>. <source>Signal Transduct. Target. Ther.</source> <volume>6</volume>:<fpage>162</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41392-021-00553-z</pub-id>, PMID: <pub-id pub-id-type="pmid">33907179</pub-id></citation></ref>
<ref id="ref48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Illes</surname> <given-names>P.</given-names></name> <name><surname>Khan</surname> <given-names>T. M.</given-names></name> <name><surname>Rubini</surname> <given-names>P.</given-names></name></person-group> (<year>2017</year>). <article-title>Neuronal P2X7 receptors revisited: do they really exist?</article-title> <source>J. Neurosci. Off. J. Soc. Neurosci.</source> <volume>37</volume>, <fpage>7049</fpage>&#x2013;<lpage>7062</lpage>. doi: <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3103-16.2017</pub-id>, PMID: <pub-id pub-id-type="pmid">28747388</pub-id></citation></ref>
<ref id="ref49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Illes</surname> <given-names>P.</given-names></name> <name><surname>M&#x00FC;ller</surname> <given-names>C. E.</given-names></name> <name><surname>Jacobson</surname> <given-names>K. A.</given-names></name> <name><surname>Grutter</surname> <given-names>T.</given-names></name> <name><surname>Nicke</surname> <given-names>A.</given-names></name> <name><surname>Fountain</surname> <given-names>S. J.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Update of P2X receptor properties and their pharmacology: IUPHAR review 30</article-title>. <source>Br. J. Pharmacol.</source> <volume>178</volume>, <fpage>489</fpage>&#x2013;<lpage>514</lpage>. doi: <pub-id pub-id-type="doi">10.1111/bph.1529</pub-id>, PMID: <pub-id pub-id-type="pmid">33125712</pub-id></citation></ref>
<ref id="ref50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Illes</surname> <given-names>P.</given-names></name> <name><surname>Rubini</surname> <given-names>P.</given-names></name> <name><surname>Ulrich</surname> <given-names>H.</given-names></name> <name><surname>Zhao</surname> <given-names>Y.</given-names></name> <name><surname>Tang</surname> <given-names>Y.</given-names></name></person-group> (<year>2020</year>). <article-title>Regulation of microglial functions by purinergic mechanisms in the healthy and diseased CNS</article-title>. <source>Cells</source> <volume>9</volume>:<fpage>1108</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cells9051108</pub-id>, PMID: <pub-id pub-id-type="pmid">32365642</pub-id></citation></ref>
<ref id="ref51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jacobson</surname> <given-names>K. A.</given-names></name> <name><surname>Civan</surname> <given-names>M. M.</given-names></name></person-group> (<year>2016</year>). <article-title>Ocular purine receptors as drug targets in the eye</article-title>. <source>J. Ocul. Pharmacol. Therapeut.</source> <volume>32</volume>, <fpage>534</fpage>&#x2013;<lpage>547</lpage>. doi: <pub-id pub-id-type="doi">10.1089/jop.2016.0090</pub-id>, PMID: <pub-id pub-id-type="pmid">27574786</pub-id></citation></ref>
<ref id="ref52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jacobson</surname> <given-names>K. A.</given-names></name> <name><surname>Delicado</surname> <given-names>E. G.</given-names></name> <name><surname>Gachet</surname> <given-names>C.</given-names></name> <name><surname>Kennedy</surname> <given-names>C.</given-names></name> <name><surname>von K&#x00FC;gelgen</surname> <given-names>I.</given-names></name> <name><surname>Li</surname> <given-names>B.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Update of P2Y receptor pharmacology: IUPHAR review 27</article-title>. <source>Br. J. Pharmacol.</source> <volume>177</volume>, <fpage>2413</fpage>&#x2013;<lpage>2433</lpage>. doi: <pub-id pub-id-type="doi">10.1111/bph.15005</pub-id>, PMID: <pub-id pub-id-type="pmid">32037507</pub-id></citation></ref>
<ref id="ref53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Junger</surname> <given-names>W. G.</given-names></name></person-group> (<year>2011</year>). <article-title>Immune cell regulation by autocrine purinergic signalling</article-title>. <source>Nat. Rev. Immunol.</source> <volume>11</volume>, <fpage>201</fpage>&#x2013;<lpage>212</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nri2938</pub-id>, PMID: <pub-id pub-id-type="pmid">21331080</pub-id></citation></ref>
<ref id="ref54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kahlenberg</surname> <given-names>J. M.</given-names></name> <name><surname>Kaplan</surname> <given-names>M. J.</given-names></name></person-group> (<year>2013</year>). <article-title>Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease</article-title>. <source>J. Immunol.</source> <volume>191</volume>, <fpage>4895</fpage>&#x2013;<lpage>4901</lpage>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1302005</pub-id>, PMID: <pub-id pub-id-type="pmid">24185823</pub-id></citation></ref>
<ref id="ref55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kayagaki</surname> <given-names>N.</given-names></name> <name><surname>Stowe</surname> <given-names>I. B.</given-names></name> <name><surname>Lee</surname> <given-names>B. L.</given-names></name> <name><surname>O'Rourke</surname> <given-names>K.</given-names></name> <name><surname>Anderson</surname> <given-names>K.</given-names></name> <name><surname>Warming</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling</article-title>. <source>Nature</source> <volume>526</volume>, <fpage>666</fpage>&#x2013;<lpage>671</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nature15541</pub-id>, PMID: <pub-id pub-id-type="pmid">26375259</pub-id></citation></ref>
<ref id="ref56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kelley</surname> <given-names>N.</given-names></name> <name><surname>Jeltema</surname> <given-names>D.</given-names></name> <name><surname>Duan</surname> <given-names>Y.</given-names></name> <name><surname>He</surname> <given-names>Y.</given-names></name></person-group> (<year>2019</year>). <article-title>The NLRP3 inflammasome: an overview of mechanisms of activation and regulation</article-title>. <source>Int. J. Mol. Sci.</source> <volume>20</volume>:<fpage>3328</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms20133328</pub-id>, PMID: <pub-id pub-id-type="pmid">31284572</pub-id></citation></ref>
<ref id="ref57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kempuraj</surname> <given-names>D.</given-names></name> <name><surname>Thangavel</surname> <given-names>R.</given-names></name> <name><surname>Natteru</surname> <given-names>P. A.</given-names></name> <name><surname>Selvakumar</surname> <given-names>G. P.</given-names></name> <name><surname>Saeed</surname> <given-names>D.</given-names></name> <name><surname>Zahoor</surname> <given-names>H.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Neuroinflammation induces neurodegeneration</article-title>. <source>J. Neurol. Neurosurg. Spine</source> <volume>1</volume>:<fpage>1003</fpage>.</citation></ref>
<ref id="ref58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kerur</surname> <given-names>N.</given-names></name> <name><surname>Hirano</surname> <given-names>Y.</given-names></name> <name><surname>Tarallo</surname> <given-names>V.</given-names></name> <name><surname>Fowler</surname> <given-names>B. J.</given-names></name> <name><surname>Bastos-Carvalho</surname> <given-names>A.</given-names></name> <name><surname>Yasuma</surname> <given-names>T.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>TLR-independent and P2X7-dependent signaling mediate Alu RNA-induced NLRP3 inflammasome activation in geographic atrophy</article-title>. <source>Invest. Ophthalmol. Vis. Sci.</source> <volume>54</volume>, <fpage>7395</fpage>&#x2013;<lpage>7401</lpage>. doi: <pub-id pub-id-type="doi">10.1167/iovs.13-12500</pub-id>, PMID: <pub-id pub-id-type="pmid">24114535</pub-id></citation></ref>
<ref id="ref59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname> <given-names>R. J.</given-names></name> <name><surname>Zeiss</surname> <given-names>C.</given-names></name> <name><surname>Chew</surname> <given-names>E. Y.</given-names></name> <name><surname>Tsai</surname> <given-names>J. Y.</given-names></name> <name><surname>Sackler</surname> <given-names>R. S.</given-names></name> <name><surname>Haynes</surname> <given-names>C.</given-names></name> <etal/></person-group>. (<year>2005</year>). <article-title>Complement factor H polymorphism in age-related macular degeneration</article-title>. <source>Science</source> <volume>308</volume>, <fpage>385</fpage>&#x2013;<lpage>389</lpage>. doi: <pub-id pub-id-type="doi">10.1126/science.1109557</pub-id>, PMID: <pub-id pub-id-type="pmid">15761122</pub-id></citation></ref>
<ref id="ref60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kronlage</surname> <given-names>M.</given-names></name> <name><surname>Song</surname> <given-names>J.</given-names></name> <name><surname>Sorokin</surname> <given-names>L.</given-names></name> <name><surname>Isfort</surname> <given-names>K.</given-names></name> <name><surname>Schwerdtle</surname> <given-names>T.</given-names></name> <name><surname>Leipziger</surname> <given-names>J.</given-names></name> <etal/></person-group>. (<year>2010</year>). <article-title>Autocrine purinergic receptor signaling is essential for macrophage chemotaxis</article-title>. <source>Sci. Signal.</source> <volume>3</volume>:<fpage>ra55</fpage>. doi: <pub-id pub-id-type="doi">10.1126/scisignal.2000588</pub-id>, PMID: <pub-id pub-id-type="pmid">20664064</pub-id></citation></ref>
<ref id="ref61"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kukulski</surname> <given-names>F.</given-names></name> <name><surname>L&#x00E9;vesque</surname> <given-names>S. A.</given-names></name> <name><surname>S&#x00E9;vigny</surname> <given-names>J.</given-names></name></person-group> (<year>2011</year>). <article-title>Impact of ectoenzymes on p2 and p1 receptor signaling</article-title>. <source>Adv. Pharmacol.</source> <volume>61</volume>, <fpage>263</fpage>&#x2013;<lpage>299</lpage>. doi: <pub-id pub-id-type="doi">10.1016/B978-0-12-385526-8.00009-6</pub-id>, PMID: <pub-id pub-id-type="pmid">21586362</pub-id></citation></ref>
<ref id="ref62"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kumar-Singh</surname> <given-names>R.</given-names></name></person-group> (<year>2019</year>). <article-title>The role of complement membrane attack complex in dry and wet AMD &#x2013; from hypothesis to clinical trials</article-title>. <source>Exp. Eye Res.</source> <volume>184</volume>, <fpage>266</fpage>&#x2013;<lpage>277</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.exer.2019.05.006</pub-id>, PMID: <pub-id pub-id-type="pmid">31082363</pub-id></citation></ref>
<ref id="ref63"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kunchithapautham</surname> <given-names>K.</given-names></name> <name><surname>Rohrer</surname> <given-names>B.</given-names></name></person-group> (<year>2011</year>). <article-title>Sublytic membrane-attack-complex (MAC) activation alters regulated rather than constitutive vascular endothelial growth factor (VEGF) secretion in retinal pigment epithelium monolayers</article-title>. <source>J. Biol. Chem.</source> <volume>286</volume>, <fpage>23717</fpage>&#x2013;<lpage>23724</lpage>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M110.214593</pub-id>, PMID: <pub-id pub-id-type="pmid">21566137</pub-id></citation></ref>
<ref id="ref64"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kur</surname> <given-names>J.</given-names></name> <name><surname>Newman</surname> <given-names>E. A.</given-names></name></person-group> (<year>2014</year>). <article-title>Purinergic control of vascular tone in the retina</article-title>. <source>J. Physiol.</source> <volume>592</volume>, <fpage>491</fpage>&#x2013;<lpage>504</lpage>. doi: <pub-id pub-id-type="doi">10.1113/jphysiol.2013.267294</pub-id>, PMID: <pub-id pub-id-type="pmid">24277867</pub-id></citation></ref>
<ref id="ref65"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kur</surname> <given-names>J.</given-names></name> <name><surname>Newman</surname> <given-names>E. A.</given-names></name> <name><surname>Chan-Ling</surname> <given-names>T.</given-names></name></person-group> (<year>2012</year>). <article-title>Cellular and physiological mechanisms underlying blood flow regulation in the retina and choroid in health and disease</article-title>. <source>Prog. Retin. Eye Res.</source> <volume>31</volume>, <fpage>377</fpage>&#x2013;<lpage>406</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.preteyeres.2012.04.004</pub-id>, PMID: <pub-id pub-id-type="pmid">22580107</pub-id></citation></ref>
<ref id="ref66"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kurashima</surname> <given-names>Y.</given-names></name> <name><surname>Amiya</surname> <given-names>T.</given-names></name> <name><surname>Nochi</surname> <given-names>T.</given-names></name> <name><surname>Fujisawa</surname> <given-names>K.</given-names></name> <name><surname>Haraguchi</surname> <given-names>T.</given-names></name> <name><surname>Iba</surname> <given-names>H.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>Extracellular ATP mediates mast cell-dependent intestinal inflammation through P2X7 purinoceptors</article-title>. <source>Nat. Commun.</source> <volume>3</volume>:<fpage>1034</fpage>. doi: <pub-id pub-id-type="doi">10.1038/ncomms2023</pub-id>, PMID: <pub-id pub-id-type="pmid">22948816</pub-id></citation></ref>
<ref id="ref67"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Latz</surname> <given-names>E.</given-names></name> <name><surname>Xiao</surname> <given-names>T. S.</given-names></name> <name><surname>Stutz</surname> <given-names>A.</given-names></name></person-group> (<year>2013</year>). <article-title>Activation and regulation of the inflammasomes</article-title>. <source>Nat. Rev. Immunol.</source> <volume>13</volume>, <fpage>397</fpage>&#x2013;<lpage>411</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nri3452</pub-id>, PMID: <pub-id pub-id-type="pmid">23702978</pub-id></citation></ref>
<ref id="ref68"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lavalette</surname> <given-names>S.</given-names></name> <name><surname>Raoul</surname> <given-names>W.</given-names></name> <name><surname>Houssier</surname> <given-names>M.</given-names></name> <name><surname>Camelo</surname> <given-names>S.</given-names></name> <name><surname>Levy</surname> <given-names>O.</given-names></name> <name><surname>Calippe</surname> <given-names>B.</given-names></name> <etal/></person-group>. (<year>2011</year>). <article-title>Interleukin-1&#x03B2; inhibition prevents choroidal neovascularization and does not exacerbate photoreceptor degeneration</article-title>. <source>Am. J. Pathol.</source> <volume>178</volume>, <fpage>2416</fpage>&#x2013;<lpage>2423</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ajpath.2011.01.013</pub-id>, PMID: <pub-id pub-id-type="pmid">21514452</pub-id></citation></ref>
<ref id="ref69"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lazarowski</surname> <given-names>E. R.</given-names></name> <name><surname>Boucher</surname> <given-names>R. C.</given-names></name> <name><surname>Harden</surname> <given-names>T. K.</given-names></name></person-group> (<year>2003</year>). <article-title>Mechanisms of release of nucleotides and integration of their action as P2X-and P2Y-receptor activating molecules</article-title>. <source>Mol. Pharmacol.</source> <volume>64</volume>, <fpage>785</fpage>&#x2013;<lpage>795</lpage>. doi: <pub-id pub-id-type="doi">10.1124/mol.64.4.785</pub-id>, PMID: <pub-id pub-id-type="pmid">14500734</pub-id></citation></ref>
<ref id="ref70"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>X.</given-names></name> <name><surname>Xia</surname> <given-names>S.</given-names></name> <name><surname>Zhang</surname> <given-names>Z.</given-names></name> <name><surname>Wu</surname> <given-names>H.</given-names></name> <name><surname>Lieberman</surname> <given-names>J.</given-names></name></person-group> (<year>2021</year>). <article-title>Channelling inflammation: gasdermins in physiology and disease</article-title>. <source>Nat. Rev. Drug Discov.</source> <volume>20</volume>, <fpage>384</fpage>&#x2013;<lpage>405</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41573-021-00154-z</pub-id>, PMID: <pub-id pub-id-type="pmid">33692549</pub-id></citation></ref>
<ref id="ref71"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lueck</surname> <given-names>K.</given-names></name> <name><surname>Wasmuth</surname> <given-names>S.</given-names></name> <name><surname>Williams</surname> <given-names>J.</given-names></name> <name><surname>Hughes</surname> <given-names>T. R.</given-names></name> <name><surname>Morgan</surname> <given-names>B. P.</given-names></name> <name><surname>Lommatzsch</surname> <given-names>A.</given-names></name> <etal/></person-group>. (<year>2011</year>). <article-title>Sub-lytic C5b-9 induces functional changes in retinal pigment epithelial cells consistent with age-related macular degeneration</article-title>. <source>Eye</source> <volume>25</volume>, <fpage>1074</fpage>&#x2013;<lpage>1082</lpage>. doi: <pub-id pub-id-type="doi">10.1038/eye.2011.109</pub-id>, PMID: <pub-id pub-id-type="pmid">21597483</pub-id></citation></ref>
<ref id="ref72"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Luibl</surname> <given-names>V.</given-names></name> <name><surname>Isas</surname> <given-names>J. M.</given-names></name> <name><surname>Kayed</surname> <given-names>R.</given-names></name> <name><surname>Glabe</surname> <given-names>C. G.</given-names></name> <name><surname>Langen</surname> <given-names>R.</given-names></name> <name><surname>Chen</surname> <given-names>J.</given-names></name></person-group> (<year>2006</year>). <article-title>Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers</article-title>. <source>J. Clin. Invest.</source> <volume>116</volume>, <fpage>378</fpage>&#x2013;<lpage>385</lpage>. doi: <pub-id pub-id-type="doi">10.1172/JCI25843</pub-id>, PMID: <pub-id pub-id-type="pmid">16453022</pub-id></citation></ref>
<ref id="ref73"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Malik</surname> <given-names>A.</given-names></name> <name><surname>Kanneganti</surname> <given-names>T. D.</given-names></name></person-group> (<year>2017</year>). <article-title>Inflammasome activation and assembly at a glance</article-title>. <source>J. Cell Sci.</source> <volume>130</volume>, <fpage>3955</fpage>&#x2013;<lpage>3963</lpage>. doi: <pub-id pub-id-type="doi">10.1242/jcs.207365</pub-id>, PMID: <pub-id pub-id-type="pmid">29196474</pub-id></citation></ref>
<ref id="ref74"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martinon</surname> <given-names>F.</given-names></name> <name><surname>Burns</surname> <given-names>K.</given-names></name> <name><surname>Tschopp</surname> <given-names>J.</given-names></name></person-group> (<year>2002</year>). <article-title>The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta</article-title>. <source>Mol. Cell</source> <volume>10</volume>, <fpage>417</fpage>&#x2013;<lpage>426</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s1097-2765(02)00599-3</pub-id></citation></ref>
<ref id="ref75"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsubara</surname> <given-names>J. A.</given-names></name> <name><surname>Tian</surname> <given-names>Y.</given-names></name> <name><surname>Cui</surname> <given-names>J. Z.</given-names></name> <name><surname>Zeglinski</surname> <given-names>M. R.</given-names></name> <name><surname>Hiroyasu</surname> <given-names>S.</given-names></name> <name><surname>Turner</surname> <given-names>C. T.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Retinal distribution and extracellular activity of granzyme B: a serine protease that degrades retinal pigment epithelial tight junctions and extracellular matrix proteins</article-title>. <source>Front. Immunol.</source> <volume>11</volume>:<fpage>574</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2020.00574</pub-id>, PMID: <pub-id pub-id-type="pmid">32318066</pub-id></citation></ref>
<ref id="ref76"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Medina</surname> <given-names>C. B.</given-names></name> <name><surname>Mehrotra</surname> <given-names>P.</given-names></name> <name><surname>Arandjelovic</surname> <given-names>S.</given-names></name> <name><surname>Perry</surname> <given-names>J. S. A.</given-names></name> <name><surname>Guo</surname> <given-names>Y.</given-names></name> <name><surname>Morioka</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Metabolites released from apoptotic cells act as tissue messengers</article-title>. <source>Nature</source> <volume>580</volume>, <fpage>130</fpage>&#x2013;<lpage>135</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41586-020-2121-3</pub-id>, PMID: <pub-id pub-id-type="pmid">32238926</pub-id></citation></ref>
<ref id="ref77"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Merle</surname> <given-names>N. S.</given-names></name> <name><surname>Church</surname> <given-names>S. E.</given-names></name> <name><surname>Fremeaux-Bacchi</surname> <given-names>V.</given-names></name> <name><surname>Roumenina</surname> <given-names>L. T.</given-names></name></person-group> (<year>2015a</year>). <article-title>Complement system part I - molecular mechanisms of activation and regulation</article-title>. <source>Front. Immunol.</source> <volume>6</volume>:<fpage>262</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2015.00262</pub-id></citation></ref>
<ref id="ref78"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Merle</surname> <given-names>N. S.</given-names></name> <name><surname>Noe</surname> <given-names>R.</given-names></name> <name><surname>Halbwachs-Mecarelli</surname> <given-names>L.</given-names></name> <name><surname>Fremeaux-Bacchi</surname> <given-names>V.</given-names></name> <name><surname>Roumenina</surname> <given-names>L. T.</given-names></name></person-group> (<year>2015b</year>). <article-title>Complement system part II: role in immunity</article-title>. <source>Front. Immunol.</source> <volume>6</volume>:<fpage>257</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2015.00257</pub-id></citation></ref>
<ref id="ref79"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname> <given-names>P.</given-names></name> <name><surname>Liew</surname> <given-names>G.</given-names></name> <name><surname>Gopinath</surname> <given-names>B.</given-names></name> <name><surname>Wong</surname> <given-names>T. Y.</given-names></name></person-group> (<year>2018</year>). <article-title>Age-related macular degeneration</article-title>. <source>Lancet</source> <volume>392</volume>, <fpage>1147</fpage>&#x2013;<lpage>1159</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(18)31550-2</pub-id></citation></ref>
<ref id="ref80"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname> <given-names>C. H.</given-names></name> <name><surname>Reigada</surname> <given-names>D.</given-names></name></person-group> (<year>2008</year>). <article-title>Purinergic signalling in the subretinal space: a role in the communication between the retina and the RPE</article-title>. <source>Purinergic signalling</source> <volume>4</volume>, <fpage>101</fpage>&#x2013;<lpage>107</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11302-007-9054-2</pub-id>, PMID: <pub-id pub-id-type="pmid">18368526</pub-id></citation></ref>
<ref id="ref81"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morciano</surname> <given-names>G.</given-names></name> <name><surname>Sarti</surname> <given-names>A. C.</given-names></name> <name><surname>Marchi</surname> <given-names>S.</given-names></name> <name><surname>Missiroli</surname> <given-names>S.</given-names></name> <name><surname>Falzoni</surname> <given-names>S.</given-names></name> <name><surname>Raffaghello</surname> <given-names>L.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Use of luciferase probes to measure ATP in living cells and animals</article-title>. <source>Nat. Protoc.</source> <volume>12</volume>, <fpage>1542</fpage>&#x2013;<lpage>1562</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nprot.2017.052</pub-id>, PMID: <pub-id pub-id-type="pmid">28683062</pub-id></citation></ref>
<ref id="ref82"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Narendran</surname> <given-names>S.</given-names></name> <name><surname>Pereira</surname> <given-names>F.</given-names></name> <name><surname>Yerramothu</surname> <given-names>P.</given-names></name> <name><surname>Apicella</surname> <given-names>I.</given-names></name> <name><surname>Wang</surname> <given-names>S. B.</given-names></name> <name><surname>Ambati</surname> <given-names>K.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Nucleoside reverse transcriptase inhibitors and Kamuvudines inhibit amyloid-&#x03B2; induced retinal pigmented epithelium degeneration</article-title>. <source>Signal Transduct. Target. Ther.</source> <volume>6</volume>:<fpage>149</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41392-021-00537-z</pub-id>, PMID: <pub-id pub-id-type="pmid">33850097</pub-id></citation></ref>
<ref id="ref83"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname> <given-names>E. A.</given-names></name></person-group> (<year>2015</year>). <article-title>Glial cell regulation of neuronal activity and blood flow in the retina by release of gliotransmitters</article-title>. <source>Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci.</source> <volume>370</volume>:<fpage>20140195</fpage>. doi: <pub-id pub-id-type="doi">10.1098/rstb.2014.0195</pub-id>, PMID: <pub-id pub-id-type="pmid">26009774</pub-id></citation></ref>
<ref id="ref84"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Niyadurupola</surname> <given-names>N.</given-names></name> <name><surname>Sidaway</surname> <given-names>P.</given-names></name> <name><surname>Ma</surname> <given-names>N.</given-names></name> <name><surname>Rhodes</surname> <given-names>J. D.</given-names></name> <name><surname>Broadway</surname> <given-names>D. C.</given-names></name> <name><surname>Sanderson</surname> <given-names>J.</given-names></name></person-group> (<year>2013</year>). <article-title>P2X7 receptor activation mediates retinal ganglion cell death in a human retina model of ischemic neurodegeneration</article-title>. <source>Invest. Ophthalmol. Vis. Sci.</source> <volume>54</volume>, <fpage>2163</fpage>&#x2013;<lpage>2170</lpage>. doi: <pub-id pub-id-type="doi">10.1167/iovs.12-10968</pub-id></citation></ref>
<ref id="ref85"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Notomi</surname> <given-names>S.</given-names></name> <name><surname>Hisatomi</surname> <given-names>T.</given-names></name> <name><surname>Kanemaru</surname> <given-names>T.</given-names></name> <name><surname>Takeda</surname> <given-names>A.</given-names></name> <name><surname>Ikeda</surname> <given-names>Y.</given-names></name> <name><surname>Enaida</surname> <given-names>H.</given-names></name> <etal/></person-group>. (<year>2011</year>). <article-title>Critical involvement of extracellular ATP acting on P2RX7 purinergic receptors in photoreceptor cell death</article-title>. <source>Am. J. Pathol.</source> <volume>179</volume>, <fpage>2798</fpage>&#x2013;<lpage>2809</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ajpath.2011.08.035</pub-id>, PMID: <pub-id pub-id-type="pmid">21983632</pub-id></citation></ref>
<ref id="ref86"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Notomi</surname> <given-names>S.</given-names></name> <name><surname>Hisatomi</surname> <given-names>T.</given-names></name> <name><surname>Murakami</surname> <given-names>Y.</given-names></name> <name><surname>Terasaki</surname> <given-names>H.</given-names></name> <name><surname>Sonoda</surname> <given-names>S.</given-names></name> <name><surname>Asato</surname> <given-names>R.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>Dynamic increase in extracellular ATP accelerates photoreceptor cell apoptosis via ligation of P2RX7 in subretinal hemorrhage</article-title>. <source>PLoS ONE</source> <volume>8</volume>:<fpage>e53338</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0053338</pub-id>, PMID: <pub-id pub-id-type="pmid">23308196</pub-id></citation></ref>
<ref id="ref87"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ogura</surname> <given-names>S.</given-names></name> <name><surname>Baldeosingh</surname> <given-names>R.</given-names></name> <name><surname>Bhutto</surname> <given-names>I. A.</given-names></name> <name><surname>Kambhampati</surname> <given-names>S. P.</given-names></name> <name><surname>Scott McLeod</surname> <given-names>D.</given-names></name> <name><surname>Edwards</surname> <given-names>M. M.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>A role for mast cells in geographic atrophy</article-title>. <source>FASEB J.</source> <volume>34</volume>, <fpage>10117</fpage>&#x2013;<lpage>10131</lpage>. doi: <pub-id pub-id-type="doi">10.1096/fj.202000807R</pub-id>, PMID: <pub-id pub-id-type="pmid">32525594</pub-id></citation></ref>
<ref id="ref88"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Orning</surname> <given-names>P.</given-names></name> <name><surname>Lien</surname> <given-names>E.</given-names></name> <name><surname>Fitzgerald</surname> <given-names>K. A.</given-names></name></person-group> (<year>2019</year>). <article-title>Gasdermins and their role in immunity and inflammation</article-title>. <source>J. Exp. Med.</source> <volume>216</volume>, <fpage>2453</fpage>&#x2013;<lpage>2465</lpage>. doi: <pub-id pub-id-type="doi">10.1084/jem.20190545</pub-id>, PMID: <pub-id pub-id-type="pmid">31548300</pub-id></citation></ref>
<ref id="ref89"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pellegatti</surname> <given-names>P.</given-names></name> <name><surname>Falzoni</surname> <given-names>S.</given-names></name> <name><surname>Pinton</surname> <given-names>P.</given-names></name> <name><surname>Rizzuto</surname> <given-names>R.</given-names></name> <name><surname>Di Virgilio</surname> <given-names>F.</given-names></name></person-group> (<year>2005</year>). <article-title>A novel recombinant plasma membrane-targeted luciferase reveals a new pathway for ATP secretion</article-title>. <source>Mol. Biol. Cell</source> <volume>16</volume>, <fpage>3659</fpage>&#x2013;<lpage>3665</lpage>. doi: <pub-id pub-id-type="doi">10.1091/mbc.e05-03-0222</pub-id>, PMID: <pub-id pub-id-type="pmid">15944221</pub-id></citation></ref>
<ref id="ref300"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pellegatti</surname> <given-names>P.</given-names></name> <name><surname>Raffaghello</surname> <given-names>L.</given-names></name> <name><surname>Bianchi</surname> <given-names>G.</given-names></name> <name><surname>Piccardi</surname> <given-names>F.</given-names></name> <name><surname>Pistoia</surname> <given-names>V.</given-names></name> <name><surname>Virgilioa</surname> <given-names>F.</given-names></name></person-group>. (<year>2008</year>). <article-title>Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase</article-title>. <source>PloS one</source>, <volume>3</volume>, <fpage>e2599</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0002599</pub-id></citation></ref>
<ref id="ref90"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Platania</surname> <given-names>C. B. M.</given-names></name> <name><surname>Lazzara</surname> <given-names>F.</given-names></name> <name><surname>Fidilio</surname> <given-names>A.</given-names></name> <name><surname>Fresta</surname> <given-names>C. G.</given-names></name> <name><surname>Conti</surname> <given-names>F.</given-names></name> <name><surname>Giurdanella</surname> <given-names>G.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Blood-retinal barrier protection against high glucose damage: the role of P2X7 receptor</article-title>. <source>Biochem. Pharmacol.</source> <volume>168</volume>, <fpage>249</fpage>&#x2013;<lpage>258</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bcp.2019.07.010</pub-id></citation></ref>
<ref id="ref91"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ralevic</surname> <given-names>V.</given-names></name> <name><surname>Burnstock</surname> <given-names>G.</given-names></name></person-group> (<year>1998</year>). <article-title>Receptors for purines and pyrimidines</article-title>. <source>Pharmacol. Rev.</source> <volume>50</volume>, <fpage>413</fpage>&#x2013;<lpage>492</lpage>. PMID: <pub-id pub-id-type="pmid">9755289</pub-id></citation></ref>
<ref id="ref92"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rasmussen</surname> <given-names>A.</given-names></name> <name><surname>Sander</surname> <given-names>B.</given-names></name></person-group> (<year>2014</year>). <article-title>Long-term longitudinal study of patients treated with ranibizumab for neovascular age-related macular degeneration</article-title>. <source>Curr. Opin. Ophthalmol.</source> <volume>25</volume>, <fpage>158</fpage>&#x2013;<lpage>163</lpage>. doi: <pub-id pub-id-type="doi">10.1097/ICU.0000000000000050</pub-id>, PMID: <pub-id pub-id-type="pmid">24663065</pub-id></citation></ref>
<ref id="ref93"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ricklin</surname> <given-names>D.</given-names></name> <name><surname>Hajishengallis</surname> <given-names>G.</given-names></name> <name><surname>Yang</surname> <given-names>K.</given-names></name> <name><surname>Lambris</surname> <given-names>J. D.</given-names></name></person-group> (<year>2010</year>). <article-title>Complement: a key system for immune surveillance and homeostasis</article-title>. <source>Nat. Immunol.</source> <volume>11</volume>, <fpage>785</fpage>&#x2013;<lpage>797</lpage>. doi: <pub-id pub-id-type="doi">10.1038/ni.1923</pub-id>, PMID: <pub-id pub-id-type="pmid">20720586</pub-id></citation></ref>
<ref id="ref94"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Romagnani</surname> <given-names>A.</given-names></name> <name><surname>Rottoli</surname> <given-names>E.</given-names></name> <name><surname>Mazza</surname> <given-names>E. M. C.</given-names></name> <name><surname>Rezzonico-Jost</surname> <given-names>T.</given-names></name> <name><surname>De Ponte Conti</surname> <given-names>B.</given-names></name> <name><surname>Proietti</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>P2X7 receptor activity limits accumulation of T cells within tumors</article-title>. <source>Cancer Res.</source> <volume>80</volume>, <fpage>3906</fpage>&#x2013;<lpage>3919</lpage>. doi: <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-19-3807</pub-id>, PMID: <pub-id pub-id-type="pmid">32699136</pub-id></citation></ref>
<ref id="ref95"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sakaki</surname> <given-names>H.</given-names></name> <name><surname>Tsukimoto</surname> <given-names>M.</given-names></name> <name><surname>Harada</surname> <given-names>H.</given-names></name> <name><surname>Moriyama</surname> <given-names>Y.</given-names></name> <name><surname>Kojima</surname> <given-names>S.</given-names></name></person-group> (<year>2013</year>). <article-title>Autocrine regulation of macrophage activation via exocytosis of ATP and activation of P2Y11 receptor</article-title>. <source>PLoS One</source> <volume>8</volume>:<fpage>e59778</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0059778</pub-id>, PMID: <pub-id pub-id-type="pmid">23577075</pub-id></citation></ref>
<ref id="ref96"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salcman</surname> <given-names>B.</given-names></name> <name><surname>Affleck</surname> <given-names>K.</given-names></name> <name><surname>Bulfone-Paus</surname> <given-names>S.</given-names></name></person-group> (<year>2021</year>). <article-title>P2X receptor-dependent modulation of mast cell and glial cell activities in Neuroinflammation</article-title>. <source>Cells</source> <volume>10</volume>:<fpage>2282</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cells10092282</pub-id>, PMID: <pub-id pub-id-type="pmid">34571930</pub-id></citation></ref>
<ref id="ref97"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sanderson</surname> <given-names>J.</given-names></name> <name><surname>Dartt</surname> <given-names>D. A.</given-names></name> <name><surname>Trinkaus-Randall</surname> <given-names>V.</given-names></name> <name><surname>Pintor</surname> <given-names>J.</given-names></name> <name><surname>Civan</surname> <given-names>M. M.</given-names></name> <name><surname>Delamere</surname> <given-names>N. A.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Purines in the eye: recent evidence for the physiological and pathological role of purines in the RPE, retinal neurons, astrocytes, M&#x00FC;ller cells, lens, trabecular meshwork, cornea and lacrimal gland</article-title>. <source>Exp. Eye Res.</source> <volume>127</volume>, <fpage>270</fpage>&#x2013;<lpage>279</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.exer.2014.08.009</pub-id>, PMID: <pub-id pub-id-type="pmid">25151301</pub-id></citation></ref>
<ref id="ref98"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Santiago</surname> <given-names>A.</given-names></name> <name><surname>Madeira</surname> <given-names>M.</given-names></name> <name><surname>Boia</surname> <given-names>R.</given-names></name> <name><surname>Aires</surname> <given-names>I.</given-names></name> <name><surname>Rodrigues-Neves</surname> <given-names>A.</given-names></name> <name><surname>Santos</surname> <given-names>P.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Keep an eye on adenosine: its role in retinal inflammation</article-title>. <source>Pharmacol. Ther.</source> <volume>210</volume>, <fpage>1</fpage>&#x2013;<lpage>22</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.pharmthera.2020.107513</pub-id>, PMID: <pub-id pub-id-type="pmid">32109489</pub-id></citation></ref>
<ref id="ref99"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sanz</surname> <given-names>J. M.</given-names></name> <name><surname>Chiozzi</surname> <given-names>P.</given-names></name> <name><surname>Ferrari</surname> <given-names>D.</given-names></name> <name><surname>Colaianna</surname> <given-names>M.</given-names></name> <name><surname>Idzko</surname> <given-names>M.</given-names></name> <name><surname>Falzoni</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2009</year>). <article-title>Activation of microglia by amyloid {beta} requires P2X7 receptor expression</article-title>. <source>J. Immunol. (Baltimore, Md.: 1950)</source>. <volume>182(7)</volume>, <fpage>4378</fpage>&#x2013;<lpage>4385</lpage>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.0803612</pub-id></citation></ref>
<ref id="ref100"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sarma</surname> <given-names>J. V.</given-names></name> <name><surname>Ward</surname> <given-names>P. A.</given-names></name></person-group> (<year>2011</year>). <article-title>The complement system</article-title>. <source>Cell Tissue Res.</source> <volume>343</volume>, <fpage>227</fpage>&#x2013;<lpage>235</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00441-010-1034-0</pub-id>, PMID: <pub-id pub-id-type="pmid">20838815</pub-id></citation></ref>
<ref id="ref101"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schramm</surname> <given-names>E. C.</given-names></name> <name><surname>Clark</surname> <given-names>S. J.</given-names></name> <name><surname>Triebwasser</surname> <given-names>M. P.</given-names></name> <name><surname>Raychaudhuri</surname> <given-names>S.</given-names></name> <name><surname>Seddon</surname> <given-names>J.</given-names></name> <name><surname>Atkinson</surname> <given-names>J. P.</given-names></name></person-group> (<year>2014</year>). <article-title>Genetic variants in the complement system predisposing to age-related macular degeneration: a review</article-title>. <source>Mol. Immunol.</source> <volume>61</volume>, <fpage>118</fpage>&#x2013;<lpage>125</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.molimm.2014.06.032</pub-id>, PMID: <pub-id pub-id-type="pmid">25034031</pub-id></citation></ref>
<ref id="ref102"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schwiebert</surname> <given-names>E. M.</given-names></name> <name><surname>Zsembery</surname> <given-names>A.</given-names></name></person-group> (<year>2003</year>). <article-title>Extracellular ATP as a signaling molecule for epithelial cells</article-title>. <source>Biochim. Biophys. Acta</source> <volume>1615</volume>, <fpage>7</fpage>&#x2013;<lpage>32</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s0005-2736(03)00210-4</pub-id></citation></ref>
<ref id="ref103"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname> <given-names>W.</given-names></name> <name><surname>Fruttiger</surname> <given-names>M.</given-names></name> <name><surname>Zhu</surname> <given-names>L.</given-names></name> <name><surname>Chung</surname> <given-names>S. H.</given-names></name> <name><surname>Barnett</surname> <given-names>N. L.</given-names></name> <name><surname>Kirk</surname> <given-names>J. K.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>Conditional Muller cell ablation causes independent neuronal and vascular pathologies in a novel transgenic model</article-title>. <source>J. Neurosci.</source> <volume>32</volume>, <fpage>15715</fpage>&#x2013;<lpage>15727</lpage>. doi: <pub-id pub-id-type="doi">10.1523/JNEUROSCI.2841-12.2012</pub-id>, PMID: <pub-id pub-id-type="pmid">23136411</pub-id></citation></ref>
<ref id="ref104"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname> <given-names>J.</given-names></name> <name><surname>Zhao</surname> <given-names>Y.</given-names></name> <name><surname>Wang</surname> <given-names>K.</given-names></name> <name><surname>Shi</surname> <given-names>X.</given-names></name> <name><surname>Wang</surname> <given-names>Y.</given-names></name> <name><surname>Huang</surname> <given-names>H.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death</article-title>. <source>Nature</source> <volume>526</volume>, <fpage>660</fpage>&#x2013;<lpage>665</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nature15514</pub-id></citation></ref>
<ref id="ref105"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shieh</surname> <given-names>C. H.</given-names></name> <name><surname>Heinrich</surname> <given-names>A.</given-names></name> <name><surname>Serchov</surname> <given-names>T.</given-names></name> <name><surname>van Calker</surname> <given-names>D.</given-names></name> <name><surname>Biber</surname> <given-names>K.</given-names></name></person-group> (<year>2014</year>). <article-title>P2X7-dependent, but differentially regulated release of IL-6, CCL2, and TNF-&#x03B1; in cultured mouse microglia</article-title>. <source>Glia</source> <volume>62</volume>, <fpage>592</fpage>&#x2013;<lpage>607</lpage>. doi: <pub-id pub-id-type="doi">10.1002/glia.22628</pub-id>, PMID: <pub-id pub-id-type="pmid">24470356</pub-id></citation></ref>
<ref id="ref106"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shinozaki</surname> <given-names>Y.</given-names></name> <name><surname>Saito</surname> <given-names>K.</given-names></name> <name><surname>Kashiwagi</surname> <given-names>K.</given-names></name> <name><surname>Koizumi</surname> <given-names>S.</given-names></name></person-group> (<year>2023</year>). <article-title>Ocular P2 receptors and glaucoma</article-title>. <source>Neuropharmacology</source> <volume>222</volume>:<fpage>109302</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuropharm.2022.109302</pub-id>, PMID: <pub-id pub-id-type="pmid">36341810</pub-id></citation></ref>
<ref id="ref107"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sorbara</surname> <given-names>M. T.</given-names></name> <name><surname>Girardin</surname> <given-names>S. E.</given-names></name></person-group> (<year>2011</year>). <article-title>Mitochondrial ROS fuel the inflammasome</article-title>. <source>Cell Res.</source> <volume>21</volume>, <fpage>558</fpage>&#x2013;<lpage>560</lpage>. doi: <pub-id pub-id-type="doi">10.1038/cr.2011.20</pub-id>, PMID: <pub-id pub-id-type="pmid">21283134</pub-id></citation></ref>
<ref id="ref108"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stahl</surname> <given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>The diagnosis and treatment of age-related macular degeneration</article-title>. <source>Deutsch. Arztebl. Int.</source> <volume>117</volume>, <fpage>513</fpage>&#x2013;<lpage>520</lpage>. doi: <pub-id pub-id-type="doi">10.3238/arztebl.2020.0513</pub-id>, PMID: <pub-id pub-id-type="pmid">33087239</pub-id></citation></ref>
<ref id="ref109"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Strauss</surname> <given-names>O.</given-names></name></person-group> (<year>2005</year>). <article-title>The retinal pigment epithelium in visual function</article-title>. <source>Physiol. Rev.</source> <volume>85</volume>, <fpage>845</fpage>&#x2013;<lpage>881</lpage>. doi: <pub-id pub-id-type="doi">10.1152/physrev.00021.2004</pub-id></citation></ref>
<ref id="ref110"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname> <given-names>Y.</given-names></name> <name><surname>Zheng</surname> <given-names>Y.</given-names></name> <name><surname>Wang</surname> <given-names>C.</given-names></name> <name><surname>Liu</surname> <given-names>Y.</given-names></name></person-group> (<year>2018</year>). <article-title>Glutathione depletion induces ferroptosis, autophagy, and premature cell senescence in retinal pigment epithelial cells</article-title>. <source>Cell Death Dis.</source> <volume>9</volume>:<fpage>753</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41419-018-0794-4</pub-id>, PMID: <pub-id pub-id-type="pmid">29988039</pub-id></citation></ref>
<ref id="ref111"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Theoharides</surname> <given-names>T. C.</given-names></name> <name><surname>Alysandratos</surname> <given-names>K. D.</given-names></name> <name><surname>Angelidou</surname> <given-names>A.</given-names></name> <name><surname>Delivanis</surname> <given-names>D. A.</given-names></name> <name><surname>Sismanopoulos</surname> <given-names>N.</given-names></name> <name><surname>Zhang</surname> <given-names>B.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>Mast cells and inflammation</article-title>. <source>Biochim. Biophys. Acta</source> <volume>1822</volume>, <fpage>21</fpage>&#x2013;<lpage>33</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bbadis.2010.12.014</pub-id>, PMID: <pub-id pub-id-type="pmid">21185371</pub-id></citation></ref>
<ref id="ref112"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thurman</surname> <given-names>J. M.</given-names></name> <name><surname>Renner</surname> <given-names>B.</given-names></name> <name><surname>Kunchithapautham</surname> <given-names>K.</given-names></name> <name><surname>Ferreira</surname> <given-names>V. P.</given-names></name> <name><surname>Pangburn</surname> <given-names>M. K.</given-names></name> <name><surname>Ablonczy</surname> <given-names>Z.</given-names></name> <etal/></person-group>. (<year>2009</year>). <article-title>Oxidative stress renders retinal pigment epithelial cells susceptible to complement-mediated injury</article-title>. <source>J. Biol. Chem.</source> <volume>284</volume>, <fpage>16939</fpage>&#x2013;<lpage>16947</lpage>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M808166200</pub-id>, PMID: <pub-id pub-id-type="pmid">19386604</pub-id></citation></ref>
<ref id="ref113"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tomasinsig</surname> <given-names>L.</given-names></name> <name><surname>Pizzirani</surname> <given-names>C.</given-names></name> <name><surname>Skerlavaj</surname> <given-names>B.</given-names></name> <name><surname>Pellegatti</surname> <given-names>P.</given-names></name> <name><surname>Gulinelli</surname> <given-names>S.</given-names></name> <name><surname>Tossi</surname> <given-names>A.</given-names></name> <etal/></person-group>. (<year>2008</year>). <article-title>The human cathelicidin LL-37 modulates the activities of the P2X7 receptor in a structure-dependent manner</article-title>. <source>J. Biol. Chem.</source> <volume>283</volume>, <fpage>30471</fpage>&#x2013;<lpage>30481</lpage>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M802185200</pub-id>, PMID: <pub-id pub-id-type="pmid">18765670</pub-id></citation></ref>
<ref id="ref114"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tseng</surname> <given-names>W. A.</given-names></name> <name><surname>Thein</surname> <given-names>T.</given-names></name> <name><surname>Kinnunen</surname> <given-names>K.</given-names></name> <name><surname>Lashkari</surname> <given-names>K.</given-names></name> <name><surname>Gregory</surname> <given-names>M. S.</given-names></name> <name><surname>D'Amore</surname> <given-names>P. A.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>NLRP3 inflammasome activation in retinal pigment epithelial cells by lysosomal destabilization: implications for age-related macular degeneration</article-title>. <source>Invest. Ophthalmol. Vis. Sci.</source> <volume>54</volume>, <fpage>110</fpage>&#x2013;<lpage>120</lpage>. doi: <pub-id pub-id-type="doi">10.1167/iovs.12-10655</pub-id>, PMID: <pub-id pub-id-type="pmid">23221073</pub-id></citation></ref>
<ref id="ref115"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ventura</surname> <given-names>A. L. M.</given-names></name> <name><surname>Mitchell</surname> <given-names>C. H.</given-names></name> <name><surname>Faillace</surname> <given-names>M. P.</given-names></name></person-group> (<year>2019</year>). <article-title>Purinergic signaling in the retina: from development to disease</article-title>. <source>Brain Res. Bull.</source> <volume>151</volume>, <fpage>92</fpage>&#x2013;<lpage>108</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.brainresbull.2018.10.016</pub-id>, PMID: <pub-id pub-id-type="pmid">30458250</pub-id></citation></ref>
<ref id="ref116"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vessey</surname> <given-names>K. A.</given-names></name> <name><surname>Gu</surname> <given-names>B. J.</given-names></name> <name><surname>Jobling</surname> <given-names>A. I.</given-names></name> <name><surname>Phipps</surname> <given-names>J. A.</given-names></name> <name><surname>Greferath</surname> <given-names>U.</given-names></name> <name><surname>Tran</surname> <given-names>M. X.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Loss of function of P2X7 receptor scavenger activity in aging mice: a novel model for investigating the early pathogenesis of age-related macular degeneration</article-title>. <source>Am. J. Pathol.</source> <volume>187</volume>, <fpage>1670</fpage>&#x2013;<lpage>1685</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ajpath.2017.04.016</pub-id>, PMID: <pub-id pub-id-type="pmid">28628761</pub-id></citation></ref>
<ref id="ref117"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname> <given-names>A. H.</given-names></name> <name><surname>Anand</surname> <given-names>V. N.</given-names></name> <name><surname>Wang</surname> <given-names>W. H.</given-names></name> <name><surname>Chatterton</surname> <given-names>J. E.</given-names></name> <name><surname>Sun</surname> <given-names>D.</given-names></name> <name><surname>Shepard</surname> <given-names>A. R.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>Exon-level expression profiling of ocular tissues</article-title>. <source>Exp. Eye Res.</source> <volume>111</volume>, <fpage>105</fpage>&#x2013;<lpage>111</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.exer.2013.03.004</pub-id>, PMID: <pub-id pub-id-type="pmid">23500522</pub-id></citation></ref>
<ref id="ref118"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wakx</surname> <given-names>A.</given-names></name> <name><surname>Dutot</surname> <given-names>M.</given-names></name> <name><surname>Massicot</surname> <given-names>F.</given-names></name> <name><surname>Mascarelli</surname> <given-names>F.</given-names></name> <name><surname>Limb</surname> <given-names>G. A.</given-names></name> <name><surname>Rat</surname> <given-names>P.</given-names></name></person-group> (<year>2016</year>). <article-title>Amyloid &#x03B2; peptide induces apoptosis through P2X7 cell death receptor in retinal cells: modulation by marine Omega-3 fatty acid DHA and EPA</article-title>. <source>Appl. Biochem. Biotechnol.</source> <volume>178</volume>, <fpage>368</fpage>&#x2013;<lpage>381</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12010-015-1878-6</pub-id>, PMID: <pub-id pub-id-type="pmid">26467741</pub-id></citation></ref>
<ref id="ref119"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wareham</surname> <given-names>K. J.</given-names></name> <name><surname>Seward</surname> <given-names>E. P.</given-names></name></person-group> (<year>2016</year>). <article-title>P2X7 receptors induce degranulation in human mast cells</article-title>. <source>Purinergic Signal.</source> <volume>12</volume>, <fpage>235</fpage>&#x2013;<lpage>246</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11302-016-9497-4</pub-id>, PMID: <pub-id pub-id-type="pmid">26910735</pub-id></citation></ref>
<ref id="ref120"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wareham</surname> <given-names>K.</given-names></name> <name><surname>Vial</surname> <given-names>C.</given-names></name> <name><surname>Wykes</surname> <given-names>R.</given-names></name> <name><surname>Bradding</surname> <given-names>P.</given-names></name> <name><surname>Seward</surname> <given-names>E.</given-names></name></person-group> (<year>2009</year>). <article-title>Functional evidence for the expression of P2X1, P2X4 and P2X7 receptors in human lung mast cells</article-title>. <source>Br. J. Pharmacol.</source> <volume>157</volume>, <fpage>1215</fpage>&#x2013;<lpage>1224</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1476-5381.2009.00287.x</pub-id>, PMID: <pub-id pub-id-type="pmid">19552691</pub-id></citation></ref>
<ref id="ref121"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname> <given-names>W. L.</given-names></name> <name><surname>Su</surname> <given-names>X.</given-names></name> <name><surname>Li</surname> <given-names>X.</given-names></name> <name><surname>Cheung</surname> <given-names>C. M.</given-names></name> <name><surname>Klein</surname> <given-names>R.</given-names></name> <name><surname>Cheng</surname> <given-names>C. Y.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis</article-title>. <source>Lancet Glob. Health</source> <volume>2</volume>, <fpage>e106</fpage>&#x2013;<lpage>e116</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S2214-109X(13)70145-1</pub-id>, PMID: <pub-id pub-id-type="pmid">25104651</pub-id></citation></ref>
<ref id="ref122"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yancopoulos</surname> <given-names>G. D.</given-names></name> <name><surname>Davis</surname> <given-names>S.</given-names></name> <name><surname>Gale</surname> <given-names>N. W.</given-names></name> <name><surname>Rudge</surname> <given-names>J. S.</given-names></name> <name><surname>Wiegand</surname> <given-names>S. J.</given-names></name> <name><surname>Holash</surname> <given-names>J.</given-names></name></person-group> (<year>2000</year>). <article-title>Vascular-specific growth factors and blood vessel formation</article-title>. <source>Nature</source> <volume>407</volume>, <fpage>242</fpage>&#x2013;<lpage>248</lpage>. doi: <pub-id pub-id-type="doi">10.1038/35025215</pub-id></citation></ref>
<ref id="ref123"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>D.</given-names></name> <name><surname>Elner</surname> <given-names>S. G.</given-names></name> <name><surname>Clark</surname> <given-names>A. J.</given-names></name> <name><surname>Hughes</surname> <given-names>B. A.</given-names></name> <name><surname>Petty</surname> <given-names>H. R.</given-names></name> <name><surname>Elner</surname> <given-names>V. M.</given-names></name></person-group> (<year>2011</year>). <article-title>Activation of P2X receptors induces apoptosis in human retinal pigment epithelium</article-title>. <source>Invest. Ophthalmol. Vis. Sci.</source> <volume>52</volume>, <fpage>1522</fpage>&#x2013;<lpage>1530</lpage>. doi: <pub-id pub-id-type="doi">10.1167/iovs.10-6172</pub-id>, PMID: <pub-id pub-id-type="pmid">21071745</pub-id></citation></ref>
<ref id="ref124"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>D.</given-names></name> <name><surname>He</surname> <given-names>Y.</given-names></name> <name><surname>Mu&#x00F1;oz-Planillo</surname> <given-names>R.</given-names></name> <name><surname>Liu</surname> <given-names>Q.</given-names></name> <name><surname>N&#x00FA;&#x00F1;ez</surname> <given-names>G.</given-names></name></person-group> (<year>2015</year>). <article-title>Caspase-11 requires the Pannexin-1 channel and the purinergic P2X7 pore to mediate pyroptosis and endotoxic shock</article-title>. <source>Immunity</source> <volume>43</volume>, <fpage>923</fpage>&#x2013;<lpage>932</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2015.10.009</pub-id>, PMID: <pub-id pub-id-type="pmid">26572062</pub-id></citation></ref>
<ref id="ref125"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>M.</given-names></name> <name><surname>So</surname> <given-names>K. F.</given-names></name> <name><surname>Lam</surname> <given-names>W. C.</given-names></name> <name><surname>Lo</surname> <given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Novel programmed cell death as therapeutic targets in age-related macular degeneration?</article-title> <source>Int. J. Mol. Sci.</source> <volume>21</volume>:<fpage>7279</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms21197279</pub-id>, PMID: <pub-id pub-id-type="pmid">33019767</pub-id></citation></ref>
<ref id="ref126"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname> <given-names>S. S.</given-names></name> <name><surname>Tang</surname> <given-names>Y.</given-names></name> <name><surname>Song</surname> <given-names>J. T.</given-names></name></person-group> (<year>2021</year>). <article-title>ATP and adenosine in the retina and retinal diseases</article-title>. <source>Front. Pharmacol.</source> <volume>12</volume>:<fpage>654445</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fphar.2021.654445</pub-id>, PMID: <pub-id pub-id-type="pmid">34211393</pub-id></citation></ref>
<ref id="ref127"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>P.</given-names></name> <name><surname>Zhang</surname> <given-names>X.</given-names></name> <name><surname>Liu</surname> <given-names>N.</given-names></name> <name><surname>Tang</surname> <given-names>L.</given-names></name> <name><surname>Peng</surname> <given-names>C.</given-names></name> <name><surname>Chen</surname> <given-names>X.</given-names></name></person-group> (<year>2021</year>). <article-title>Pyroptosis: mechanisms and diseases</article-title>. <source>Signal Transduct. Target. Ther.</source> <volume>6</volume>:<fpage>128</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41392-021-00507-5</pub-id>, PMID: <pub-id pub-id-type="pmid">33776057</pub-id></citation></ref>
<ref id="ref128"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>W.</given-names></name> <name><surname>Zhou</surname> <given-names>S.</given-names></name> <name><surname>Liu</surname> <given-names>G.</given-names></name> <name><surname>Kong</surname> <given-names>F.</given-names></name> <name><surname>Chen</surname> <given-names>S.</given-names></name> <name><surname>Yan</surname> <given-names>H.</given-names></name></person-group> (<year>2018</year>). <article-title>Multiple steps determine CD73 shedding from RPE: lipid raft localization, ARA1 interaction, and MMP-9 up- regulation</article-title>. <source>Purinergic Signal.</source> <volume>14</volume>, <fpage>443</fpage>&#x2013;<lpage>457</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11302-018-9628-1</pub-id>, PMID: <pub-id pub-id-type="pmid">30392016</pub-id></citation></ref>
<ref id="ref129"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname> <given-names>D.</given-names></name> <name><surname>Liwinski</surname> <given-names>T.</given-names></name> <name><surname>Elinav</surname> <given-names>E.</given-names></name></person-group> (<year>2020</year>). <article-title>Inflammasome activation and regulation: toward a better understanding of complex mechanisms</article-title>. <source>Cell Discov.</source> <volume>6</volume>:<fpage>36</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41421-020-0167-x</pub-id>, PMID: <pub-id pub-id-type="pmid">32550001</pub-id></citation></ref>
<ref id="ref130"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>R.</given-names></name> <name><surname>Yazdi</surname> <given-names>A. S.</given-names></name> <name><surname>Menu</surname> <given-names>P.</given-names></name> <name><surname>Tschopp</surname> <given-names>J.</given-names></name></person-group> (<year>2011</year>). <article-title>A role for mitochondria in NLRP3 inflammasome activation</article-title>. <source>Nature</source> <volume>469</volume>, <fpage>221</fpage>&#x2013;<lpage>225</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nature09663</pub-id></citation></ref>
<ref id="ref131"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zumerle</surname> <given-names>S.</given-names></name> <name><surname>Cal&#x00EC;</surname> <given-names>B.</given-names></name> <name><surname>Munari</surname> <given-names>F.</given-names></name> <name><surname>Angioni</surname> <given-names>R.</given-names></name> <name><surname>Di Virgilio</surname> <given-names>F.</given-names></name> <name><surname>Molon</surname> <given-names>B.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Intercellular calcium signaling induced by ATP potentiates macrophage phagocytosis</article-title>. <source>Cell Rep.</source> <volume>27</volume>, <fpage>1</fpage>&#x2013;<lpage>10.e4</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.celrep.2019.03.011</pub-id>, PMID: <pub-id pub-id-type="pmid">30943393</pub-id></citation></ref>
</ref-list>
</back>
</article>